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Abstract
ALEX STEVEN WOODELL. The Alternative Complement Pathway Mediates
Chronic Smoke-Induced Functional and Morphological Ocular Injury. (Under the
direction of BÄRBEL ROHRER).
BACKGROUND: Age-related macular degeneration (AMD), a complex disease
involving genetic variants and environmental insults, is among the leading
causes of blindness in Western populations. Genetic and histologic evidence
implicate the complement system in AMD pathogenesis, and smoking is the
major environmental risk factor associated with increased disease risk. Although
previous studies have demonstrated that cigarette smoke exposure (CE) causes
retinal pigment epithelium (RPE) defects in mice and smoking leads to
complement activation in patients, it is unknown whether complement activation
is causative in the development of CE pathology; and if so, which complement
pathway is required.
METHODS: Mice were exposed to cigarette smoke or clean, filtered air for 6
months. The effects of CE were analyzed in wildtype (WT) mice or mice without a
functional complement alternative pathway (AP; CFB−/−) using molecular,
histological, electrophysiological, and behavioral outcomes. A modified AP
inhibitor, CR2-FH, was administered to WT mice for 3 months following CE to
determine the effects of anti-complement-based-therapy on smoke-induced
ocular pathology.
RESULTS: CE in WT mice exhibited a significant reduction in function of rods
and cones as determined by electroretinography and contrast sensitivity

xii

measurements, concomitant with a thinning of nuclear layers as measured by
SD-OCT imaging and histology. Gene expression analyses suggested that
alterations in photoreceptors and RPE/choroid may contribute to the observed
loss of function, and visualization of complement C3d deposition implies the
RPE/Bruch's membrane (BrM) complex as the target of AP activity. RPE/BrM
alterations include an increase in mitochondrial size concomitant with an apical
shift in mitochondrial distribution within the RPE and a thickening of BrM. CFB−/−
mice were protected from developing CE-mediated alterations, and treatment
with CR2-FH reversed existing damage in WT mice.
CONCLUSIONS: Taken together, these findings provide clear evidence that
ocular pathology generated in CE mice is dependent on complement activation
and requires the AP. Identifying animal models with RPE/BrM damage and
verifying which aspects of pathology are dependent upon complement activation
is essential for developing novel complement-based treatment approaches for
the treatment of AMD.
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CHAPTER 1
INTRODUCTION AND SPECIFIC AIMS
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Introduction
The first manifestations of senile macular degeneration were described in
medical literature by the British ophthalmologist, Waren Tay, as “symmetrical
central choroidoretinal disease occurring in senile persons.” This was renamed to
its current alias, age-related macular degeneration (AMD), in the 1980s. AMD is
a chronic, progressive eye disease that results in loss of central vision and is the
leading cause of severe vision loss and blindness in Western populations. Vision
loss occurs due to degeneration of the macula, the portion of the retina
responsible for sharp, central vision. There are two major forms of AMD: atrophic
(dry) and exudative (wet). 85-90% of AMD cases are atrophic, while only 10-15%
represent the exudative form. Dry AMD is characterized by the formation of
small, yellow deposits beneath the retina, called drusen, that are made up of
metabolic end products generated by the retinal pigment epithelium (RPE).
Patients experience a slow, progressive loss of vision which may start as blurred
or distorted spots in the visual field. Over time, large areas of retinal thinning
called geographic atrophy (GA) can develop causing severe vision loss. Wet
AMD is characterized by a rapid loss of vision caused by abnormal blood vessel
growth through Bruch’s membrane (BrM) which then leak blood and proteins into
the subretinal space. Over time, scar tissue can form near areas of
neovascularization that can lead to the formation of subretinal abrasions known
as disciform scars. Current estimates show that as many as 11 million people in
the United States over the age of 50 have some form of AMD, and this number is
expected to double by 2020. There is a substantial global burden of AMD with
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projections of 196 million by 2020 and 288 million by 2040 [1]. The annual cost of
AMD is estimated to be approximately $30 billion [2]. Data pooled from three
population-based studies, the Beaver Dam Eye Study, the Rotterdam Study, and
the Blue Mountain Eye Study, estimated the prevalence rate for AMD is about
0.2% for individuals between 55-64 years, sharply increasing to 13% in those
over the age of 85 [3].
Pathology of AMD
The progression of AMD occurs over an extended period of time, with the
incidence of disease increasing dramatically over the age of 70 [4]. AMD is a
multifactorial disease that primarily affects the RPE, overlying photoreceptors,
BrM, and choriocapillaris (CC). The main pathological features associated with
AMD vary with the stage of disease. Here, we focus on the primary features of
early/advanced stage, dry AMD (drusen formation and GA) and late stage, wet
AMD (subretinal neovascularization and disciform scar formation).
The hallmark indicators of early stage, dry AMD are pigmentary changes
in the macula and the formation of drusen. In 1855, drusen were first described
by Franciscus Donders, a Dutch ophthalmologist and one of the primary founders
of scientific opthalmology [5]. He initially referred to them as “colloidkugeln” or
colloid spheres. The German anatomist, Heinrich Müller, later gave them their
name, derived from the German word for geodes, cavities in rocks often lined by
crystals, based on their glittering appearance [6]. Drusen appear as small,
yellow-white spots in the retina and are most often found as clusters within the
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macular region. They are composed of complement proteins, inflammatory
molecules, lipids, lipoproteins B and E, and glycoproteins [7] and are located
between the basement membrane of the RPE and the inner collagenous layer
(ICL) of BrM. Due to their position between the RPE and CC, it is possible that
drusen impede the transfer of oxygen and nutrients from the vascular blood
supply to the RPE and overlying photoreceptor cells. Likewise, they may also
interfere with waste products being removed from the RPE. Clinically, drusen are
classified morphologically as hard or soft. Hard drusen are small (<63 µm),
round, isolated from one another, and have sharp borders. These are more
common with age, but are mostly benign and not commonly associated with
vision problems. In contrast, soft drusen are large (≥63 µm), variable in shape,
have less defined borders, and tend to cluster close together. These are thought
to be more harmful and are associated with a greater risk for developing AMD,
including choroidal neovascularization (CNV) and GA [8].
Drusen are associated with outer retina thinning in early/intermediate AMD
[9]. Specifically, the photoreceptor outer nuclear layer (ONL) is thinner in areas
overlying drusen, and corresponding photoreceptor inner and outer segment
(OS) length is also reduced [10]. Furthermore, there is a strong correlation
between retinal thinning and drusen height [9], rather than width. Retinal thinning
in the photoreceptor layer suggests a degenerative process, with cell loss leading
to decreased visual function. This hypothesis is supported by optical coherence
tomography (OCT) imaging of hyperreflective foci that are visible above drusen in
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the ONL, likely representing photoreceptor degeneration and/or glial scar
formation
A phenotypically distinct type of drusen, called called reticular
pseudodrusen (RPD), were first described in 1990 as “les pseudodrusen bleus”
due to their enhanced visibility under blue light [11]. RPD are subretinal deposits
which appear as yellowish interlacing macular networks in the fundus. RPD
accumulate above the RPE, between the apical membrane of the RPE and the
IS/OS boundary. RPD are associated with an increased risk for progressing to
both neovascular AMD and GA [12].
In addition to drusen, accumulation of other deposit types is associated
with AMD. Basal laminar deposits (BLamD) and basal linear deposits (BLinD) are
subretinal deposits primarily comprised of phospholipids. BLamDs are found
between the plasma and basement membranes of the RPE, while BLinDs are
located external to the RPE basement membrane in the ICL of BrM. BLamDs
may progress to BLinDs, which are associated with soft drusen and RPE
detachments [13]. BLinDs are good markers for progression to late stage AMD,
while the amount of BLamDs is associated with the degree of RPE atrophy and
photoreceptor degeneration [14-16].
The primary clinical characteristic of advanced stage, dry AMD is the
appearance of retinal thinning, also known as GA. This is visualized as sharply
delineated round or oval areas of hypopigmentation (>175 µm), signifying the
absence of RPE, in which choroidal vessels are more visible than surrounding
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areas [17]. According to the Age-Related Eye Disease Study (AREDS), the most
common sequence of events leading to GA is the progression of a large drusen
to hyperpigmentation, followed by regression of the drusen, hypopigmentation,
and finally RPE cell death. Studies suggest that RPE cells are the primary target
in GA and its death results in CC atrophy [18, 19]. In most cases, GA starts near
the center of the macula and progresses outward to the periphery, forming
islands of lost photoreceptor cells. The average enlargement rate of atrophic
area is about 2.6 mm2/year and eyes with larger baseline atrophy have even
higher enlargement rates [20]. As these areas of atrophy grow, blind spots, called
scotomas, form in patients’ visual field caused by photoreceptor cell death. The
decrease in number of rods, reduction in foveal cone function, and shift from
central to eccentric fixation all contribute to a decrease in contrast sensitivity,
reading rate, and dark adaptation in GA [21-23]. Decreases in rod-mediated dark
adaptation are also consistent with normal aging and AMD, independent of GA
[24].
CNV is the defining feature of late stage, wet AMD. Neovascularization
has two distinct etiologic patterns. The first and most common description of CNV
is the growth of new vessels from the CC through BrM into the subretinal space
[25]. The second, involves the development of vessels derived from retinal
circulation in a process called retinal angiomatous proliferations (RAP), also
known as deep retinal vascular anamalous complex or retinochoroidal
anastomosis [26, 27]. These vessels extend outward from the neurosensory
retina into the subretinal space, sometimes anastomosing with choroid-derived
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vessels [28]. However, RAP occurs much less frequently than classical choroidderived neovascularization. Central vision loss can occur rapidly once CNV
begins, and hemorrhaging of new blood vessels can accelerate the onset of
vision loss. Ultimately, photoreceptors die from lack of nutrients, leakage of
serum components from CNV, and scar formation [29]. Blood leakage and serous
exudate resulting from CNV can also cause pigment epithelial detachment, a
process in which the RPE separates from the underlying BrM [30].
Left untreated, the natural course of late stage, wet AMD advances further
to develop fibrous disciform scars, a result of subretinal neovascularization.
Fibrous tissue can develop within BrM or between the RPE and retina resulting in
a fibrotic scar (4-8 mm) underlying the macula. This is often accompanied by a
central scotoma and causes severe vision loss. Hemoserdin is typically present
in the lesions, suggesting hemorrhaging, a consequence of CNV, occurs prior to
scar formation. Disciform scars cause the overlying retina to undergo cystic
degeneration with photoreceptor loss. Blindness from neovascular wet AMD is
associated with macular disciform scar formation and 360° peripapillary
subretinal fibrosis, which may cause ischemic optic neuropathy [31]. Disciform
scars may contribute to vision loss by creating an expanding band of RPE
atrophy, possibly due to remodeling of choroidal circulation [32]. Interestingly,
patients with bilateral disciform scars reported visual improvement in the first
affected eye after development of scarring in both eyes [33].
A growing body of literature suggests that dysfunctional mitochondria may
lie at the core of AMD etiology [34, 35]. Feher et al. [36] have reported age7

related changes in mitochondrial morphology as analyzed in histological
sections, that are accentuated in AMD. Aged RPE contain mitochondria that
show membrane disorganization, a focal loss of cristae, and disruption of their
apical-basal alignment. Work by He and Tombran-Tink [37] showed that cultured
RPE cells from aged donor eyes contain large, fused mitochondria that generate
less ATP than those obtained from young donors. RPE with reduced levels of
ATP, a model of aged RPE in vitro, show reduced autophagy, OS phagocytic
capacity, and increased oxidative load [38]. These studies suggest that
dysfunctional mitochondria may impair the ability of the RPE to maintain it’s role
in homeostasis due to an ATP deficiency.
The vascular model of AMD proposed by Friedman and coworkers
suggests that changes in the choroidal vasculature, similar to those observed in
atherosclerosis, are responsible for the development of AMD [39]. Chronic smoke
exposure has been shown to change clot dynamics and alter fibrin structure, both
of which contribute to thrombosis [40]. Thromboregulatory functions might be
further disrupted by a smoke-induced decrease in NTPDase, a plasmamembrane-bound enzyme that breaks down precursor nucleotides into the
antithrombotic and anti-inflammatory mediator, adenosine [41]. Smoke also
induces vasoconstriction by activating alpha-adrenergic receptors. Collectively,
these findings result in a decrease in choroidal blood flow. Friedman and
colleagues proposed that this decrease in choroidal blood flow may impair the
clearance of debris from the RPE and lead to the formation of deposits in BrM
[42]. A decrease in blood flow might also be responsible for heat-related damage

8

in the RPE/choroid, since light absorption by melanosomes results in an increase
in temperature above 37° C [43]. Cigarette smoke might be responsible for
inducing changes in angiogenesis. Smoke exposure can change the branching
pattern in proliferating vessels of chick chorioallantoic membrane [44],
concomitant with an increase in the number of fibroblasts and altered
composition of the extracellular matrix present in these membranes affecting their
structural integrity.
Risk Factors Associated with AMD
AMD is a complex disease with multiple demographic, environmental, and
genetic risk factors. Among the demographic and environmental risk factors
associated with AMD, such as age, gender, race, exposure to sunlight, diet,
smoking, education, and cardiovascular disease, studies have shown that the
most consistent are increasing age and cigarette smoking [45]. Numerous genes
have also been implicated as possible risk factors for AMD, with the strongest
association between genes involved in immune modulation and the complement
system [46-50]. Genetic predisposition to AMD may increase susceptibility to
demographic and environmental risk factors as well.
Aging
Age is the strongest risk factor associated with AMD. All population-based
studies indicate that the prevalence of AMD increases with age in caucasians
[14, 17, 51, 52]. According to the Blue Mountains Eye Study, the 5-year incidence
rate of AMD increased from 3.2% (≤60 years) to 7.4% (60-69 years) to 18.3%
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(70-79 years) in a population with no previous history of the disease [53]. These
findings parallel those of the Beaver Dam Eye Study, which found that AMD risk
increases more than three-fold in patients older than 75 years of age compared
to those between 65-74 years [54]. The age-associated increase in AMD risk
may be caused by gradual, cumulative damage to the retina as a result of
chronic oxidative stress over a long period of time. The RPE acts as a
specialized epithelial cell layer that provides metabolic support to overlying
photoreceptor cells. Loss of physiological function due to oxidative stress may
impair their ability to support photoreceptors, resulting in degeneration of these
specialized, light-sensitive cells. Alternatively, age-related mitochondrial DNA
damage may also play a role in pathogenesis.
Cigarette Smoke and Oxidative Stress
Cigarette smoke is the only proven, modifiable risk factor associated with
AMD. Previous studies found a two- to four-fold increased risk for developing
AMD in smokers compared to nonsmokers [55]. Furthermore, smoking promotes
the progression of AMD from the atrophic to neovascular form [56]. In addition to
these epidemiological studies, some genetic studies have identified geneenvironment interactions between genetic risk factors and smoking in AMD. For
example, Chakravarthy and colleagues confirmed a gene-environment
interaction between age-related maculopathy susceptibility 2 (ARMS2) and
cigarette smoke [57]; interactions between complement factor H and smoking
have been found in some populations [58], but not others [59]; and variations in
two single-nucleotide polymorphisms of apolipoprotein E were positively or
10

negatively associated with smoking in a genotype-specific manner [60]. Despite
the links between smoking and AMD, little is known of the underlying cellular
mechanisms by which cigarette smoke contributes to the pathology of AMD.
There are several major mechanistic theories in the literature that contribute to
AMD pathogenesis including oxidative stress, antioxidant depletion, complement
activation and vascular changes.
Oxidative stress, in reference to the cellular damage caused by an inability
of biological systems to detoxify reactive oxygen species (ROS), has been
implicated in a number of disease processes. ROS include superoxide, hydrogen
peroxide, hydroxyl radicals, and other byproducts of oxygen metabolism. These
ROS can damage all components of the cell, including proteins, lipids, and DNA,
as well as disrupt cellular signaling pathways.
Previous studies have shown that oxidative stress, involving the RPE in
particular, is a major contributing factor in the etiology of AMD [61]. The RPE
layer is exposed to potentially high levels of photo-oxidative stress from
photoreceptor turnover and high levels of oxygen from the systemic circulation,
which is, however, minimized due to the presence of endogenous antioxidants. If
the detoxification system is compromised, oxidants and stimulators of cellular
oxidative metabolism can then induce damage, potentially leading to apoptosis
[62]. Without support from RPE cells, overlying photoreceptors will eventually
undergo apoptosis, leading to permanent vision loss. This oxidative stress
hypothesis is supported by the AREDS, which shows that nutritional
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supplementation with antioxidants and zinc reduces the risk of early AMD
patients progressing to advanced stages of AMD by approximately 25% [63].
With each inhalation, cigarette smoke introduces a large number of free
radicals [64] and likely contributes to oxidative damage loads. Oxidants found in
cigarette smoke can pass through the alveolar walls and enter the systemic
circulation, exerting widespread effects as evidenced by an increase in plasma
markers of lipid peroxidation after smoking [65]. Oxidative damage can manifest
itself in a variety of ways, including degradation of intracellular organelles,
disruption of cell signaling pathways, and alterations in mitochondrial DNA.
Fujihara and coworkers have shown that mice exposed to chronic cigarette
smoke display signs of oxidative damage concomitant with ultrastructural
changes including RPE damage and apoptosis, and thickening of BrM [66]. In
addition to generating short-lived ROS, cigarette smoke contains a number of
stable compounds which are also capable of generating oxidative damage. Most
notable of these are acrolein, an unsaturated aldehyde capable of inducing
protein modifications and enhancing the formation of advanced glycation end
products and advanced lipid end products [67]; cadmium, a metal associated
with zinc production that accumulates in the RPE and choroid, where it generates
ROS [68]; and hydroquinone, a pro-oxidant compound, which itself can be
oxidized and conjugated with glutathione to form potent mitochondrial toxins or
cause DNA damage by covalently binding with DNA and inducing DNA oxidation
via redoxcycling [69]. All three compounds have been shown to be associated
with RPE cell damage using either in vitro or in vivo models [68, 70, 71].
12

Aerobic organisms have integrated antioxidant systems to protect against
oxidant-mediated cell damage. However, under pathological conditions these
safeguards can easily become overwhelmed. Diet-derived vitamins B, C, and E
provide protection by reacting with free radicals and preventing their propagation
in tissues. However, plasma levels of vitamin C and carotenes are significantly
lower in cigarette smokers when compared to nonsmokers [72], presumably as a
consequence of enhanced turnover due to smoke-induced oxidative stress.
Panda and colleagues supported this line of evidence by inhibiting smokeinduced oxidative damage in vivo with vitamin C supplementation [73]. Smoke
exposure also reduces the amount of endogenous circulating antioxidants; more
specifically, glutathione and cysteine were both downregulated in smokers
compared to nonsmokers [74]. Lastly, enzymes that degrade ROS and produce
endogenous antioxidants such as superoxide dismutase (SOD) are also
imperative in cellular defense against oxidative damage. SOD levels have been
shown to be decreased in tissues of smokers [75], and eliminating SOD2 in mice
results in “retinal damage similar to that associated with the early stages of agerelated macular degeneration” [76].
Inflammation
It has long been recognized that inflammation plays a role in AMD, despite
the fact that it does not present itself with the classical signs of inflammation such
as heat and swelling. However, inflammatory processes, possibly being triggered
by local cell damage or the accumulation of debris at the level of BrM, as well as
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the invasion of inflammatory cells, have been documented in eyes of AMD
patients. These local inflammatory alterations might then be propagated by the
immune system, the choroidal vascular network, and other local cells.
The complement cascade is an integral part of the innate and adaptive
immune system. Its main function is to help clear pathogens or nonself cells from
the organism by either marking them for clearance by phagocytosis or by direct
lysis. Several complement components have been found in drusen, BrM, and
CNV membranes, and severity of AMD is correlated with the amount of
complement membrane attack complex present at the level of the RPE/BrM [77].
Given the destructive potential of this system, a large number of complement
inhibitors are expressed by the host or self-cells. However, the majority of these
membrane-bound inhibitors are misregulated in AMD [78, 79].
The inflammatory hypothesis gained further support when several genetic
risk factors associated with AMD were identified as polymorphisms in
complement genes such as complement inhibitor, complement factor H (CFH),
complement factor B (CFB), and complement component 3 (C3) [80], and when
some of these gene alterations were found to be associated with the progression
of atrophic to neovascular AMD. Hence, complement therapeutics are currently
being explored for the treatment of AMD [81].
Cigarette smoke has been shown to directly activate the complement
cascade via modification of C3 and subsequently activate the alternative pathway
(AP) of complement [82]. Circulating CFH, the inhibitor of the AP, is also reduced
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in smokers. While it has yet to be proven that smoking increases the risk for AMD
by increasing complement activation, it is plausible that the combination of
complement-related genetic risk factors and smoke-induced activation of the
complement cascade may act synergistically to promote inflammation in
AMD.
Genetic Susceptibility
A large body of literature suggests that there are numerous genetic risk
factors involved in AMD [83, 84]. Several population-based studies implicate a
familial component in the pathogenesis of AMD [85-87], including monozygotic
and dizygotic twin studies. Klaver and colleagues estimated that siblings of
individuals with late stage AMD have a five-fold increased risk for developing
intermediate AMD and a twenty-fold increased risk for developing advanced AMD
[86]. Furthermore, an attributable risk study conducted by Seddon and
colleagues revealed that 80% of incident AMD is attributable to genetic factors
[88].
Many of the genes implicated in AMD risk involve a single nucleotide
polymorphism (SNP) in which one amino acid within the protein is substituted for
another. SNPs are typically a result of missense mutations, a point mutation in
which a single nucleotide change results in a codon for a different amino acid.
SNPs can have variable outcomes depending on the amino acid that is
substituted. Mutations that give rise to substitution of similar amino acids (i.e.
valine for alanine) may not modify the protein at all. However, substitution of
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amino acids with different reactivity or charge (i.e. tyrosine for leucine) can
modify the protein structure by changing the number of disulphide bridges and/or
altering hydrophobicity and charge. This can compromise protein function and
affect intermolecular interactions with other molecules. Another less common
form of substitution occurs when a premature stop codon is created via a point
mutation. The result is a truncated, incomplete, and usually nonfunctional protein
product. SNPs often occur as natural allelic variations within the population
conferring increased risk for or protection from AMD.
Evidence for a major inflammatory component in AMD pathology stems
from the association of many complement proteins including CFB, complement
component 2 (C2), and C3 with disease [89, 90]. However, the gene coding for
CFH, a regulatory inhibitor of the AP of complement, was the first significant gene
implicated in the pathogenesis of AMD [91-93]. In 2005, several groups identified
a SNP, Y402H, located within the 1q32 chromosome region, corresponding to
human CFH that was associated with AMD in several independent families. This
provided one of the first prediction models for the prevalence and incidence of
AMD [94]. The Y402H risk variant is associated with lifetime incidence of early
AMD and progression from early to late stage AMD [95]. Numerous other risk
alleles have since been identified linking CFH to AMD including rs1410996,
rs551397, and rs900292 [96, 97]. Furthermore, mutations in genes coding for the
complement factor H related proteins (CFHR), which bind to the central
complement component C3b during regulation, can result in hybrid proteins with
altered recognition domains, impairing their inhibitory function [98].
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Changes on the long (q) arm of chromosome 10 in a region known as
10q26 are also associated with AMD risk. The 10q26 region contains two genes
of interest: ARMS2 and HtrA serine peptidase 1 (HTRA1). However, because of
their close proximity, it is difficult to determine which gene is associated with AMD
risk, or if variations in both genes contribute to disease pathology. The function of
the protein encoded by ARMS2 has yet to be elucidated, but is thought to play a
role in diseases of the elderly. The association of ARMS2 with AMD risk has been
shown in numerous studies [99-102]. The ARMS2/LOC387715 SNP, A69S, is the
most well-known polymorphism associated with AMD. Heterozygosity at ARMS2/
LOC387715 (A69A/A69S) is associated with an odds ratio (OR) of 1.69-3.0 for
advanced AMD, while homozygosity for the risk allele (A69S/A69S) results in an
OR of 2.20-12.1 [101]. HTRA1 encodes serine protease HTRA1, an enzyme
involved in regulating the availability of insulin-like growth factors (IGF) by
cleaving IGF-binding proteins. IGFs are important for the regulation of normal
physiology by promoting cell proliferation and inhibiting apoptosis. One of the first
studies linking HTRA1 to AMD showed that the risk allele of rs11200638
correlated with a higher level of HTRA1 mRNA in blood lymphocytes and a
higher level of HTRA1 protein in human RPE [46]. This correlation has since
been replicated in archived retinas as well as fresh placenta tissues [103, 104].
The Complement System
The complement system was first recognized in the late 19th century
when microbiologists Paul Ehrlich, Jules Bordet, and George Nuttall discovered a
heat-sensitive component of blood had antimicrobial activity against anthrax
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bacilli [105-108]. They noted the antimicrobial activity of this component was
inactivated when blood was heated above 55° C and named it “alexine.” Later
research on guinea pigs demonstrated that the antimicrobial activity of blood was
dependent on both heat-sensitive “alexin” and another heat-stable factor which
we now call antibodies. In 1899, Paul Ehrlich renamed “alexin” to “complement”
based on the fact that it complements cells of the innate immune system [107].
The basic functions of complement are opsonization, chemotaxis, cell
lysis, and agglutination. Opsonization refers to the process of marking a
pathogen for ingestion and elimination by a phagocyte. During opsonization, an
opsonin binds to the outer membrane of a pathogen and attracts phagocytes to
the location. Chemotaxis describes the movement of cells toward or away from a
chemical stimulus. This is illustrated by complement through the attraction of
macrophages and neutrophils to sites of inflammation. Cell lysis refers to the
rupture of a cell due to viral, enzymatic, or osmotic mechanisms which
compromise the outer membrane, and is the end result of complement activation.
Agglutination is defined as the clumping or clustering of pathogens into a single,
large complex. This increases the efficiency of phagocytes, enabling them to
eliminate more pathogens with one pass. The complement system consists of
over 40 proteins and cell surface receptors. At sites of infection, the complement
system is activated locally, usually through binding of an antibody to an antigen.
This sets in motion a series of cleavages known as the complement cascade.
Complement activation can occur via three major amplification pathways (Fig.
1.1).
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Figure 1.1 The complement system. The three pathways of complement activation. Classical,
lectin, and alternative pathways converge at the point of C3 activation. The lytic pathway then
leads to the assembly of the membrane attack complex that destroys infectious agents.
Regulators of the alternative pathway CFH, CFI, and MCP cooperate to inactivate endothelial cell
surface-bound C3b, thus protecting endothelial cells from complement attack. CFH, factor H; CFI,
factor I; CFB, factor B; CFD, factor D; MCP, membrane cofactor protein [109].

The classical pathway (CP) is antibody-dependent and is initiated when a
molecule of C1q, the first protein in the complement cascade, binds directly to
the surface of a pathogen or to an antibody-antigen complex. In the latter case,
only IgM or IgG are capable of sufficient complement activation. A single
pentameric IgM can activate the pathway, but at least two monomeric IgG
molecules are required. C1q binding leads to conformational changes in the C1q
molecule, enabling activation of C1r, a serine protease, which then cleaves C1s.
The resulting C1r2s2 complex then splits C4 into C4a and C4b. C4b binds to the
surface of the pathogen and activates C2 by cleaving it into C2a and C2b. C2b
diffuses away while C2a remains attached to C4b, forming the classical C3
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convertase, C4b2a. The C3 convertase cleaves C3 into C3a and C3b, which
binds to the C3 convertase forming the classical C5 convertase, C4b2a3b.
Formation of the C5 convertase initiates the terminal pathway described below.
In contrast to the CP, the AP is antibody-independent and continuously
activated at baseline, similar to a car engine idling, as a result of spontaneous C3
hydrolysis. C3 hydrolysis occurs due to the breakdown of the internal thioester
bond resulting in the formation of C3(H2O). C3(H2O) binds to CFB, allowing
complement factor D (CFD) to split CFB into Ba and Bb components. Ba diffuses
away while Bb remains attached to C3(H2O), forming the alternative C3
convertase, C3(H2O)Bb. This compound is unstable and requires binding of
properdin, a serum protein, which extends the half-life 10-fold. The C3
convertase then splits C3 into C3a and C3b. C3b is capable of forming new C3
convertase along with CFB and CFD, thus forming an amplification loop. This
amplification loop is critical for accelerating complement attack when triggered by
one of the other two pathways. C3b can also bind to the C3 convertase forming
the alternative C5 convertase, C3(H2O)BbC3b, which initiates the terminal
pathway described below. Constant control of this pathway via complement
regulators is critical to protect the host from undesireable and potentially harmful
complement activation [110].
The lectin pathway (LP) is initiated by the binding of mannose-binding
lectin (MBL) to mannose residues on a pathogen. IgM can also bind to antigens,
providing a binding site for MBL [111]. MBL binding activates the MBL-associated
serine proteases, MASP-1 and MASP-2, which cleave C4 and C2 into C4a, C4b
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and C2a, C2b, respectively. A third serine protease, MASP-3, has been found to
have an inhibitory affect against MASP-2 [112]. C4b and C2a then combine to
form the classical C3 convertase. The LP then proceeds as previously described
to form the classical C5 convertase, initiating the terminal pathway. Ficolins can
also activate the LP by forming active complexes with mannose-binding lectinassociated serine proteases (MASP). Structurally similar to MBLs, ficolins are
soluble collagen-like proteins that bind to sugars on microorganisms and dying
host cells. There are three distinct ficolins: ficolin-1 (M-ficolin), ficolin-2 (L-ficolin),
and ficolin-3 (H-ficolin).
The terminal pathway describes the final stage of all three activation
pathways. This sequence begins with the cleavage of C5 into C5a and C5b. C5a
diffuses away while C5b remains bound to the pathogen. This is followed by the
association of C6, forming a hydrophilic C5bC6 complex. C7 binds to C5bC6,
resulting in a conformational change that exposes a hydrophobic site on C7
which allows insertion of the complex into the phospholipid bilayer of the
pathogen. C8 is a molecule made up of two proteins: C8-beta and C8-alphagamma. C8-beta has a hydrophobic region which allows it to attach to the
complex in the bilayer. The final step involves the binding of 10-15 C9 proteins
via C8-alpha-gamma, forming a cylindrical, transmembrane pore with a diameter
of approximately 10 angstroms. The pore, commonly known as the membrane
attack complex (MAC), allows free diffusion of molecules both into and out of the
cell. This may lead to osmotic imbalance through the constant flow of ions, water,
and other small molecules along their concentration gradient, ultimately resulting
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in cell lysis [113]. Sublytic complement activation can also occur, leading to
NLRP3 inflammasome activation [114]. The resulting inflammatory response can
be protective or damaging. Sublytic complement attack protects tumor cells from
lytic doses of complement [115] and attenuates reperfusion injury through the
formation of C5a [116], but also causes vascular endothelial growth factor
(VEGF) secretion in RPE cells which can lead to CNV .
Anaphylatoxins are protein fragments produced as part of the complement
system [117]. They can trigger degranulation of endothelial cells, mast cells, and
phagocytes, producing a local inflammatory response. In addition, they mediate
smooth muscle cell contraction, vascular permeability, and chemotaxis [118].
During the complement cascade, glycoproteins C3, C4, and C5 are cleaved into
a- and b-fragments. The a-fragments form distinct structural domains
approximately 76 amino acids in length and are called anaphylatoxins (i.e. C3a,
C4a, C5a). Studies suggest that locally generated anaphylatoxins contribute to
pathological processes in inflammatory and immunological diseases as well as
the adaptive immune response [119].
Complement factor H
CFH is an essential regulatory inhibitor of the alternative complement
pathway. This protein is critical for prevention of undesirable complement
activation on host cells and tissues, especially in the kidney. CFH has two
primary functions: (1) decay-accelerating activity and (2) cofactor activity. CFH
inhibits the AP through factor I-mediated inactivation of C3(H2O) or by displacing

22

Bb from the C3(H2O)Bb complex [120]. CFH is translated as a single polypeptide
of 1,213 amino acids in length. This polypeptide chain is divided into 20 similar
subunits, called short consensus repeats (SCR). The amino-terminus (SCRs 1-4)
is involved in regulatory activity. CFH binds to C3(H2O) at these domains, acting
as an antagonist for CFB, thus reducing formation of the alternative C3
convertase. CFH is more effective when C3(H2O) residues reside on the host
cell due to the presence of markers recognized by CFH. The carboxy-terminus
(SCRs 19-20) is responsible for surface binding and self/non-self recognition.
CFH binds to host markers (i.e. sialic acids and sulfated glycosaminoglycans) at
these domains and prevents the amplification cascade of the AP, while allowing
complement activation to proceed on pathogens lacking these markers. The
ability of CFH to distinguish between pathogens and host cells is crucial to
maintaining a healthy immune response. Mutations in CFH coding for these
domains lead to activation of the AP in inherited uremic syndrome [121].
The AP is continuously activated in the fluid phase, and tissue surfaces
require constant complement inhibition in order to prevent cellular injury [122].
CFH reaches blood plasma concentrations of 500-800 µg/ml, making it the
second most abundant plasma protein after human serum albumin [123]. Thus,
under normal conditions, CFH is sufficient to inhibit activation of the AP. However,
CFH seems to function differently in oxidative environments. Thurman and
colleagues showed that treatment of ARPE-19 cells with H2O2 results in a
decreased ability of CFH to control C3 conversion at the cell surface [124]. This
may reflect a reduction in expression of decay accelerating factor or an inability
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of CFH to deal with the increased C3 production. Alternatively, targeting of CFH
to cell surfaces may be impaired in oxidative environments. Malondialdehyde
(MDA) has been postulated to serve as a ligand on cell surfaces to recruit CFH
and prevent complement attack [125]. After exposing ARPE-19 cells to H2O2,
CFH is unable to bind MDA, thereby negating the inhibitory effect [126]. This
evidence of impaired CFH targeting under oxidative conditions provide the
rationale for using a modified CFH protein with a complement receptor 2 (CR2)
targeting domain to circumvent the aforementioned problems.
Goals and Specific Aims
AMD, a complex neurodegenerative disease involving genetic variants
and environmental insults, is among the leading causes of blindness in the
Western world. Genetic and histological evidence implicate the complement
system in AMD pathogenesis, and smoking is the primary environmental risk
factor associated with increased disease risk. Previous studies have shown that
cigarette smoke exposure (CE) causes RPE defects in mice and leads to
complement activation in patients. However, it is unknown whether complement
activation is causative in the development of CE pathology; and if so, which
complement pathway is required and the mechanism of action this pathway
propagates. The primary goal of this study is to determine the role of the
alternative complement pathway in cigarette smoke-induced ocular pathology.
This will be examined using an AP knockout mouse to observe differences in
visual acuity, gene expression, and retinal morphology, following chronic cigarette
smoke exposure. The secondary goal of this study is to evaluate the feasibility of
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the cigarette smoke model for studying AMD pathology. The efficacy of this
model will be determined by looking for parallels between AMD pathology and
cigarette smoke-induced ocular pathology.
Cigarette smoke is the only proven, modifiable risk factor for AMD.
Previous studies have shown that smoking increases the risk of developing AMD
two- to four-fold [55]. The pathophysiology of cigarette smoke and AMD is
complex and likely involves a number of different mechanisms. The RPE is under
a high degree of oxidative stress from the turnover of photoreceptor OS.
Cigarette smoke introduces many more free radicals [64] and likely contributes to
oxidative damage loads. Smoking also depletes antioxidants (vitamin C, E,
carotenoids [72, 73, 127, 128], glutathione, cysteine, methylumbelliferone
glucuronide, and ferroxidase [74, 129]), which act as natural oxidation inhibitors
and help clear free radicals from the system. Oxidative stress has been shown to
impair mitochondrial structure and function [130]. Lastly, cigarette smoke can
directly cleave C3, a central constituent of the complement cascade, into C3a
and C3b, since it modifies C3 in a way that diminishes binding to CFH [82]. C3b
can then bind to a membrane to trigger complement activation. Importantly, the
majority of C3b deposited on cell surfaces appears to be due to activity of the AP
amplification loop (80-90% for CP [131] and LP [132]). Based on these
observations, we hypothesize that CE will increase the amount of oxidative
stress in the the RPE, resulting in dysfunctional mitochondria, impaired retinal
pigment epithelium-Bruch’s membrane-choriocapillaris (RPE-BrM-CC) complex
structure and function, and ultimately decreased visual function. Furthermore, we
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hypothesize that the AP of the complement system contributes to in CE
pathology and that inhibition of this pathway is protective. This hypothesis will be
tested by the following specific aims. Aims 1 and 2 will be discussed together in
Chapter 2, while Aim 3 will be discussed in Chapter 3.
Specific Aim 1. Determine behavioral, functional, and morphological
deficits associated with long-term cigarette smoke
exposure in WT mice.
Specific Aim 2. Determine whether AP activation is required for the
development of CE pathology.
Specific Aim 3. Determine whether smoke-induced ocular pathology is
amenable to anti-complement-based therapy.
There is growing evidence linking oxidative stress and smoking, as well as
complement activation to the development and progression of AMD. Our studies
examine the role of the AP of complement in CE-induced AMD pathology. The
proposed experiments offer insight into the role of complement in the
development of AMD and suggest that behavioral, functional, and morphological
deficits may be amenable to complement based therapy. A better understanding
of the complement pathway is critical to the development of novel therapeutics
and treatment of this macular dystrophy.
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CHAPTER 2
ALTERNATIVE PATHWAY DEFICIENCY AMELIORATES SMOKE-INDUCED
OCULAR INJURY
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Introduction
AMD is one of the leading causes of blindness in the elderly among
Western populations. AMD is a common, late-onset maculopathy that can be
diagnosed in one of two forms: atrophic, “dry”; or neovascular, “wet” [133]. The
atrophic form of the disease is best characterized by the presence of deposits
rich in lipoprotein known as drusen (≥63 µm in size) in the subretinal space
between BrM and the RPE in the macular region of the eye, and may also be
associated with pigmentary abnormalities. These alterations can be easily
visualized in patients through fundoscopic imaging. The neovascular form is
typically associated with proliferation of the choroidal blood vessels through BrM
into the subretinal space. These vessels then leak blood and proteins either into
the subretinal or sub-RPE space [134], leading to increased photoreceptor cell
death. Although patients can be diagnosed with either form of the disease, the
atrophic form is the most common, making up 90 percent of all cases [2].
AMD is a complex, multifaceted disease that is influenced by genetic and
environmental factors. Several of the main genetic risk factors are
polymorphisms occurring in complement genes, including the AP inhibitor, CFH
[91-93, 135], CFB [89], C2 [89], and C3 [89, 90]. Several of these complement
components have been found to be associated with pathological features of
AMD. Drusen present in donor eyes of patients with confirmed dry AMD, contain
complement components, beta-amyloid, and other inflammatory factors [136].
AP components and inhibitors as well as C3 have been shown to localize to the
RPE, BrM, and choroid in humans [137]. This same tissue is also immunopositive
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for MAC proteins, and it appears that MAC immunoreactivity is correlated with
AMD severity and loss of RPE cells [138]. Furthermore, genotype-phenotype
correlations have revealed associations between CFH risk alleles. Alleles that
generate less effective CFH [139] result in peripheral drusen of increased size
and reticular pigment [140, 141]. Conversely, the protective allele of CFB, which
is a less efficient activator of the AP [142], is associated with smaller drusen and
a reduced area covered by those drusen [143]. Taken together, there appears to
be a correlation between the degree of pathology and amount of activation in the
AP of complement.
The complement cascade is an integral part of the innate immune system,
as it “complements” the ability of antibodies to clear pathogens or other “non-self”
cells from an organism. There are three initiation pathways (classical, lectin, and
alternative) involved, that all lead to a common terminal pathway [144]. The CP is
initiated when C1q, a pattern recognition molecule complex, binds to the surface
of a pathogen or to an antibody:antigen complex. The LP can be initiated by the
binding of a complex between MBL and MASP or ficolin, and MASP to mannosecontaining carbohydrates on bacteria, viruses, or unprotected cell surfaces. The
AP is activated when either a spontaneously generated C3b molecule or one
generated by either the CP or the LP binds to the surface of a pathogen or
unprotected cell surfaces. All three pathways converge by forming a protease
called C3 convertase, triggering the common terminal pathway. This final
pathway is involved in executing the basic functions of the complement system.
Convertase activity generates soluble anaphylatoxins involved in attracting
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macrophages and neutrophils, as well as cell-bound opsonins involved in
removal of pathogens and cells. Finally, MAC formation, by virtue of its ability to
form a non-specific pore in the cell membrane, is involved in cell lysis. Important
for our study, the AP also provides an amplification loop for the CP and LP such
that over 80% of C3 convertase deposited onto cells is derived from AP
activation rather than the initiating pathway [131, 132]. Given the destructive
capacity of the complement cascade, this system is tightly regulated by a number
of inhibitors expressed by the host cells. These inhibitors include both cellattached as well as soluble inhibitors that prevent complement activation on
healthy self-cells. However, the levels as well as the cellular localization of these
inhibitors are influenced by environmental factors, including oxidative stress [145]
or cigarette smoke [146, 147].
Cigarette smoke is the only proven, modifiable risk factor for AMD.
Previous studies have shown that smoking increases the risk of developing AMD
2–4-fold [55]. In addition, smoking also promotes the progression of AMD from
the atrophic to neovascular form [56]. This progression may occur up to 10 years
earlier in smokers compared to non-smokers [53]. However, cessation has been
shown to reduce the risk of developing AMD and progression to the neovascular
form [148]. The pathophysiology of cigarette smoke and AMD is complex and
likely involves a number of different mechanisms. The RPE is under a high
degree of oxidative stress from the turnover of photoreceptor OS. Cigarette
smoke introduces many more free radicals [64] and likely contributes to oxidative
damage loads. Smoking also depletes antioxidants (vitamin C, E, carotenoids
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[72, 73, 127, 128], glutathione, cysteine, methylumbelliferone glucuronide, and
ferroxidase [74, 129]) which act as natural oxidation inhibitors and help clear free
radicals from the system. Cigarette smoke can directly activate C3, the primary
constituent of the complement cascade, since it modifies C3 in a way that
diminishes binding to CFH [82]. Lastly, nicotine found in cigarette smoke exerts a
vasoconstrictive action via α-adrenergic receptor activation which reduces
choroidal blood flow [149]. This reduction in choroidal circulation may underlie
depositions in BrM due to inefficient clearance of debris from the RPE [42]. Taken
together, although smoking increases the risk of AMD and leads to complement
activation, there is no conclusive evidence that smoking-related pathology is the
result of complement activation.
Given the aforementioned lines of evidence, we tested whether pathology
is dependent upon complement activation by exposing mice to long-term
cigarette smoke. Previous studies using the same model have documented
activation of the terminal pathway of the complement system in the RPE and
choroid, concomitant with damage to the RPE and photoreceptors [66, 70,
150-152]. However, little is known concerning which complement pathway might
be involved. In the present study we investigated the role of the AP. We
hypothesized that AP-deficient mice would be protected from smoke-induced
deficits based on the observation that the majority of C3 activated on cell
surfaces appears to be due to activity of the AP amplification loop (80–90% for
CP [131] and LP [132]).
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Materials and Methods
Animals
CFB −/− mice on a C57BL/6J background were generously provided by V.
Michael Holers (University of Colorado Health Science Center, Denver, CO).
C57BL/6J (also referred to as WT) mice were purchased (Jackson laboratory,
Bar Harbor, ME) [153]. Mice were confirmed to be negative for the RD8 locus by
PCR using published primers (Fig. 2.1). See Appendix for details. Animals were
housed under a 12:12 h, light:dark cycle with access to food and water ad
libitum.
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Figure 2.1 Genotyping for CFB and RD8 in WT and CFB −/− mice. DNA was isolated
from WT and CFB −/− mice, amplified with PCR primers, and resolved on a 1.5% agarose
gel containing ethidium bromide for one hour. Gels were visualized under UV light. (A) PCR
primers for complement factor B (CFB) were used to confirm the presence or absence of
CFB. Lane 1 represents a GeneRuler 100 bp Plus DNA ladder. Amplified DNA samples
from WT mice reveal a band at 748 bp which corresponds to the Amplicon CFB wild type
allele (lane 2), whereas CFB −/− mice reveal a band at 610 bp which corresponds to the
CFB knockout allele (lane 3). (B) PCR primers for RD8 were used to confirm that both
genotypes were RD8 positive. Lane 1 represents a 50 bp HyperLadderV. Amplified DNA
samples from WT mice reveal a band at 220 bp which corresponds to the Amplicon RD8
wild type allele (lane 2) and no RD8 mutant band (lane 3). Amplified DNA samples from
CFB −/− mice show the same genetic profile (lane 4, 5).

For electroretinography (ERG) or OCT imaging, mice were anesthetized
using intraperitoneal injections of xylazine and ketamine (20 and 80 mg/kg,
respectively), and pupils were dilated (2.5% phenylephrine HCl and 1% atropine
sulfate). Hydroxypropyl methylcellulose (GenTeal, 0.3%) was used as an
adherent for the contact lens electrode or was applied regularly throughout the
imaging process to maintain corneal hydration. All experiments were approved by
the Medical University of South Carolina Institutional Animal Care and Use
Committee and performed in accordance with the Association for Research in
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Vision and Ophthalmology statement for the use of animals in ophthalmic and
vision research.
Exposure to Cigarette Smoke
Eight-week-old C57BL/6J and CFB −/− male mice were divided into two
groups (n = 12 per group and genotype). The control group was kept in a filtered
air environment, and the experimental groups were subjected to cigarette smoke.
CE was carried out (5 hours per day, 5 days per week) by burning 3R4F
reference cigarettes (University of Kentucky, Louisville, Kentucky, USA) using a
smoking machine (Model TE-10; Teague Enterprises) for 6 months. The average
concentration of total suspended particulates was 130 mg/m3 and was monitored
twice daily.
Electroretinography
ERG recordings and data analyses were performed as previously
described [81] using the EPIC-2000 system (LKC Technologies, Inc.). In short,
mice were dark-adapted overnight prior to testing. ERG responses were obtained
using light stimuli with varying light intensities and wavelengths. Under scotopic
conditions, responses to 10 µs single-flashes of white light (maximum intensity of
2.48 cd m−2) between 40 and 0 db of attenuation were measured. After lightadapting animals for 2 min with rod-saturating light [154], UV-cone responses
were tested using LED flashes centered at 360 nm. Peak a-wave amplitude was
measured from baseline to the initial negative-going voltage, whereas peak bwave amplitude was measured from the trough of the a-wave to the peak of the
positive b-wave.
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Optokinetic Response Test
Visual acuity and contrast sensitivity of mice were measured by observing
their optomotor responses to moving sine-wave gratings (OptoMotry) as
previously described [155]. Mice reflexively respond to rotating vertical gratings
by moving their head in the direction of grating rotation. To observe these
movements, mice were placed individually on the central elevated pedestal
surrounded by a square array of computer monitors that display stimulus
gratings. Mice were monitored via an overhead closed-circuit TV camera that
allowed the observer to view only the central platform and not the rotating
grating. Mice were allowed to adjust to the chamber for 2 min with the monitors
displaying a 50% gray uniform field prior to testing, and monitors returned to a
homogenous gray between trials. All tests were conducted under photopic
conditions with a mean luminance of 52 cd m−2. Visual acuity was measured by
finding the spatial frequency threshold of each animal at a constant speed (12
deg/s) and contrast (100%) with a staircase procedure that systematically
increased the spatial frequency of the grating until the animal no longer exhibited
detectable responses. Contrast sensitivity was determined by taking the
reciprocal of the contrast threshold at a fixed spatial frequency (0.131 cyc/deg)
and speed (12 deg/s). It has previously been determined that this spatial
frequency falls within the range of maximal contrast sensitivity for 9-month-old
C57BL/6J mice (data not shown). Contrast of the pattern was decreased
systematically in a staircase manner until the animal stopped responding.
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Quantitative RT-PCR
RPE/choroid/sclera (henceforth referred to as RPE/choroid) and retina
fractions were isolated from control and smoke-exposed animals and stored at
−80°C until they were used. Quantitative RT-PCR (QRT-PCR) analyses were
performed as previously described in detail [156]. In short, real-time PCR
analyses were performed in triplicate in a GeneAmp® 5700 Sequence Detection
System (Applied Biosystems) using standard cycling conditions. Quantitative
values were obtained by the cycle number, normalizing genes of interest to βactin, and determining fold difference between room air and CE within
genotypes. Fold difference values were compared using Z-test analyses,
accepting a significance of P<0.05. See Table 2.1 for a full list of primers used for
QRT-PCR.
Table 2.1 Quantitative QRT-PCR primer sequences. Forward and reverse primers are listed for
each gene assayed along with the associated symbol. Hemolytic complement is also known as
complement component 5, C5. Serine (or cysteine) peptidase inhibitor, clade F, member 1 is also
known as pigment epithelium-derived factor, PEDF.
Gene name

Symbol

Forward primer

Reverse primer

rhodopsin

Rho

5’CTTCCCCATCAAC
TTCCTCA-3’

5’GAATCCTCCGAAG
ACCATGA-3’

opsin 1 (cone pigments), shortwave-sensitive (color blindness,
tritan)

Opn1sw

5’TTGGGCTCTGTAG
CAGGTCT-3’

5’CAAGTAGCCAGGA
CCACCAT-3’

opsin 1 (cone pigments),
medium-wave-sensitive (color
blindness, deutan)

Opn1mw

5’TCATTTCCTGGGA
GAGATGG-3’

5’TCCATATAGCAGC
CCAGACC-3’

retinal pigment epithelium 65

Rpe65

5’TTCTGAGTGTGGT
GGTGAGC-3’

5’AGTCCATGGAAGG
TCACAGG-3’

complement component 3

C3

5’TGAACAAGGGGAA
GCTCCT-3’

5’CAGGCGAAATGAA
GGAATA-3’
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hemolytic complement

Hc

5'TAAAACAAGGGGT
GGTGAGC-3'

5'CACCTGTCCAAGC
ACTCTCA-3'

complement component 9

C9

5'AGCATTTTAGCCTT
CGGACA-3'

5'CCTGCCTGTCTCA
CACTGAA-3'

complement factor B

Cfb

5’GGTGCCTCACCAA
CTTGATT-3’

5’CTTGGTGTTGGTC
CCTGACT-3’

complement factor D (adipsin)

Cfd

5’CAAGCGATGGTAT
GATGTGC-3’

5’CTCGTATTGCAAG
GGTAGGG-3’

complement component factor
H

Cfh

5’TGGACTTCCTTGT
GGACCTC-3’

5’CCATCAATTCCAAA
GCCTGT-3’

complement factor properdin

Cfp

5'GCTCAGGACCAGC
CTATGAG-3'

5'TGTCCGTTGCTCT
AGGGTCT -3'

CD55 antigen

Cd55

5’TAATGCGAGGGGA
AAGTGAC-3’

5’GTGGACTGCTCCA
TTGTCCT-3’

CD59a antigen

Cd59a

5’CTGCTTCTGGCTG
TGTTCTG-3’

5’TCCTGGTCAGGAG
AGCAAGT-3’

vascular endothelial growth
factor A

Vegfa

5’CTGGACCCTGGCT
TTACTGC-3’

5’TGAACTTGATCAC
TTCATGGGACT-3’

serine (or cysteine) peptidase
inhibitor, clade F, member 1

Serpinf1

5’CCTCAGCATCCTT
CTCCTTG-3’

5’TGACATCATGGGG
ACTCTCA-3’

hypoxia inducible factor 1, alpha
subunit

Hif1a

5’GAAATGGCCCAGT
GAGAAAA-3’

5’CTTCCACGTTGCT
GACTTGA-3’

ceruloplasmin

Cp

5’ATAATCAACCTGTT
CCCTGCCA-3’

5’GCAACCCAGCTTT
CAGATGGT-3’

lysozyme 1

Lyz1

5’CCAGTGTCACGAG
GCATTTA-3’

5’TGATAACAGGCTC
ATCTGTCTCA-3’

lysosomal-associated
membrane protein 2

Lamp2

5’CACCCACTCCAAC
TCCAACT-3’

5’TTGTGGCAGGGTT
GATGTTA-3’
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microtubule-associated protein
1 light chain 3 alpha

Map1lc3a

5’CGGCTTCCTGTAC
ATGGTTT-3’

5’ATGTGGGTGCCTA
CGTTCTC-3’

mitofusin 1

Mfn1

5’GGAGGATGTGCG
CAGACAGCA-3’

5’CCGATTCCGAGCT
TCCGACGG-3’

mitochondrially encoded
cytochrome c oxidase I

mt-Co1

5’TGACTTGCAACCC
TACACGGAGGTA-3
’

5’TCGTGAAGCACGA
TGTCAAGGGATG-3
’

dynamin 1-like

Dnm1l

5’GGCGCTGATCCCG
GTCATCAA-3’

5’GAGCTCTTCCCAC
TGCTCTGCG-3’

NADH dehydrogenase
(ubiquinone) 1 beta subcomplex
8

Ndufb8

5’AGGAATCGTGTGG
ACACGTCACCT-3’

5’CCACAGGCTGGTA
GGAAGGGAACA-3’

6-phosphofructo-2-kinase/
fructose-2,6-biphosphatase 2

Pfkfb2

5’GGAACAGCTTTAC
GCCTCTG-3’

5’TTCTTGCATGTCC
AGAGCAC-3’

heme oxygenase (decycling) 1

Hmox1

5’AGGCTAAGACCGC
CTTCCTGCT-3’

5’GGCAGTATCTTGC
ACCAGGCTAGC-3’

actin, beta

Actb

5'AGCTGAGAGGGAA
ATCGTGC-3'

5'ACCAGACAGCACT
GTGTTG-3'

SD-OCT Imaging
SD-OCT was performed using a Bioptigen Spectral Domain Ophthalmic
Imaging System (Bioptigen Inc., Durham, NC). The system is equipped with a
probe and platform designed for mice that allows for easy orientation and
alignment of the central retina.
Imaging and data analysis were performed with Bioptigen® InVivoVue
software. Rectangular volume scans were taken in the nasal quadrant from the
optic disc, each volume consisting of 33 B-scans (1,000 A-scans per B-scan).
Five separate scans were collected and averaged to generate a high resolution
image. Vertical calipers were placed to measure the ONL and inner nuclear layer
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(INL) for each scan. All measurements were taken 500 µm from the optic disc.
Data reflects the average of both eyes per animal.
Tissue Preparation
The eyes were enucleated, and a slit was cut into the cornea to allow for
rapid influx of fixative. Eyes were fixed overnight in 2.5% glutaraldehyde, 1%
formaldehyde, 3% sucrose, and 1 mM MgSO4 in 0.1 M cacodylate buffer, pH 7.4.
The eyes were then dissected and small central portions were osmicated for 60
minutes in 0.5% OsO4 in 0.1 M cacodylate buffer, processed in maleate buffer for
en bloc staining with uranyl acetate, dehydrated in graded ethanols, and
processed for resin embedding as in [157]. Serial sections were cut at 90 nm on
a Leica Ultramicrotome onto carbon-coated Formvar® films supported by nickel
slot-grids.
Ultrastructural Analysis
Transmission electron micrographs (EM) were captured using a JEOL
JEM 1400 transmission electron microscope using SerialEM software to
automate image capture overnight with 1200–1500 images captured per section,
yielding datasets that were then processed with the NCR Toolset [158, 159] to
generate image mosaics with corrections for image aberrations induced by
electron microscopy.
Electron microscopy images were evaluated using Adobe® Photoshop®
and ImageJ software. For each animal, two RPE cells were outlined using the
apical processes and the basal lamina (thickness) as well as the basolateral
walls (length) as borders. A masking-layer for all mitochondria present within an
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RPE cell was created to calculate average mitochondrial number and size. To
determine mitochondrial position, the centroid coordinates for each
mitochondrion was calculated as a percentage of the corresponding RPE length
and thickness, respectively. Coordinates were assigned to basolateral, basal,
central, or apical compartments based on normalized X-Y coordinates. The
density of basal laminar (BL) infoldings was determined by dividing the area
occupied by individual infoldings, by the total BL area for each of the two RPE
cells. The BL area was isolated for each RPE cell in Photoshop®. Images were
binarized, processed using a median filter (10 px radius) to reduce background
noise, and analyzed for area measurements. BrM thickness was determined by
analyzing ~13 µm mean length of BrM adjacent to each of the outlined RPE cells.
A masking layer was created over the ICL along each segment of BrM using
RPE-BrM and the middle elastic layer (MEL) as boundaries. The area of the
masking layer was divided by the length of the segment to determine an average
BrM ICL thickness. For OS width, eight OS were randomly sampled from each
animal, measuring the width at the thickest point and calculating an average.
Müller cell percent area was determined by subtracting the area occupied by the
rod/cone somas in a ~600 µm2 area of the ONL and dividing by the total area
analyzed; using the same masking technique as described from BrM thickness
analysis.
Mitochondrial distribution profiles were generated by performing a percent
normalization on the coordinates of centroids for all mitochondria with respect to
the length/width of the RPE cell they were imaged from. After plotting the data,
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we assigned each mitochondrion to one of 4 bins as follows: basolateral (x-value
<0.20 or x-value >0.80), basal (0.20≤ x-value ≤0.80 and y-value <0.33), central
(0.20≤ x-value ≤0.80 and 0.33≤ y-value <0.66), and apical (0.20≤ x-value ≤0.80
and 0.66≤ y-value <1). Significance values were based on the percentage of
mitochondria that fall into each bin.
Immunohistochemistry
Paraffin-embedded mouse eyes were sectioned at 5 µm and
immunostained for the presence of complement deposition using an antibody
(Ab) to C3, split-fragment C3d (R&D Systems, Volcano, CA).
Immunohistochemistry staining was performed as previously described [160]. In
brief, primary-Ab binding was visualized using the Vector Laboratories
ImmunoEdge detection kit and diaminobenzidinechromogen development
(Vector Laboratories, Burlingame, CA). Specificity of staining was assessed by
omission of primary Ab and the use of isotype controls. To assess the cellular
and spatial localization of C3d immunostaining, eye sections were pretreated in
30% hydrogen peroxide for 18 hours to bleach melanin deposits prior to
immunostaining, as previously described [161].
Statistics
For data consisting of multiple groups, repeated measures analysis of
variance (ANOVA) followed by the Fisher post hoc test (P<0.05) was used; single
comparisons were analyzed using the Student t-test assuming equal variance
(P<0.05; Statview; SAS Institute, Inc.). Fold changes in QRT-PCR experiments
were analyzed using a Z-test (P<0.05).
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Results
Effect of AP Deficiency on Smoke-Induced Impairment of Visual Function
Dry AMD in patients is associated with thickening of BrM that can
eventually lead to photoreceptor degeneration [162, 163]. Even without cell loss,
the structural changes in BrM can lead to impaired nutrient exchange between
the choroid and the RPE (reviewed in [164]), as well as a reduction in the
generation and delivery of the vitamin-A-based chromophore, 11-cis retinal, to
the photoreceptor outer segments [165]. In patients, these AMD-associated
pathologies lead to a reduction in visual function as measured by ERG, as well
as changes in visual acuity and contrast sensitivity.
Here, ERG recordings were assessed to determine the impact of 6
months of CE on mouse retinal function. ERG responses were analyzed under
dark-adapted, scotopic conditions to determine rod photoreceptor function, as
well as under photopic conditions after light-adaptation, to determine cone
function. Here, the focus was on the mouse UV-cones, which have been shown
to be more susceptible to perturbations (summarized in [166]) and can be
isolated spectrally by ERG. For both scotopic and photopic ERGs, the b-wave
amplitudes were reported, which are a mass potential generated by the bipolar
cells that sum photoreceptor output (reviewed in [167]). Six months of CE caused
an overall reduction in scotopic ERG amplitudes in WT animals (P<0.001) (Fig.
2.2A). While the b-wave responses of the smoke-exposed animals were
marginally reduced when compared to non-exposed controls at lower light
intensities (40, 30 dB), the differences reached significance at higher stimulus
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intensities (20, 10, 6, 0 dB; P<0.05). Likewise, the maximum UV-cone response
after CE was reduced in WT mice by ~30% (P<0.001). The photoreceptor cell
response (a-wave), which drives the b-waves, was equally affected (data not
shown). In contrast, photoreceptor cell function was significantly preserved in
smoke-exposed CFB −/− mice (P = 0.5), irrespective of whether rod or UV-cone
function was assessed (Fig. 2.2B). However, while rod ERG amplitudes have
previously been found not to differ between age-matched WT and CFB −/− mice
at 3-months-of-age [81], both rod and cone ERG amplitudes are reduced by 20–
30% across all light intensities by 9-months-of-age (P<0.01) (Fig. 2.3).
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Figure 2.2 Electroretinography analysis for WT and CFB −/− mice following CE.
ERG recordings were performed in cohorts of age-matched WT (A) and CFB −/− (B)
mice exposed to 6 months of cigarette smoke (CE) or room air. Dark-adapted,
scotopic ERGs were recorded in response to increasing light intensities, and lightadapted photopic UV-cone ERGs to a single, maximum light intensity. Scotopic ERGs
were analyzed using multiple ANOVA, followed by comparison of individual light
intensities using t-test analyses. WT mice exposed to smoke had significantly lower
dark-adapted b-wave amplitudes compared to controls (P<0.001), in particular at
higher light intensities (20, 10, 6, 0 dB). Impairment in cone function is evidenced by
the reduction in maximum UV-cone b-wave amplitudes. In comparison, ERG
amplitudes in both scotopic and photopic ERGs were unaffected in AP-deficient mice
exposed to smoke. Photoreceptor cell responses (a-waves), which drive the b-waves,
were equally affected (data not shown). Data are expressed as mean ±SEM (n = 6-8
per condition; *, P<0.05; **, P<0.001).
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Figure 2.3 Electroretinography analysis for WT and CFB −/− mice at baseline.
ERG recordings were performed in cohorts of age-matched WT and CFB −/− mice
exposed to room air for 6 months. Dark-adapted, scotopic ERGs were recorded in
response to increasing light intensities, and light-adapted photopic UV-cone ERGs to
a single, maximum light intensity. Using multiple ANOVA, CFB −/− mice had lower darkadapted b-wave amplitudes compared to WT mice (P<0.05), although when individual
light intensities were compared by t-test analysis, significance was only obtained at
the highest light intensity (0 dB), suggesting that rod function is largely intact.
However, cone function does appear to be impaired in CFB −/− mice as evidenced by
the reduction in maximum UV-cone b-wave amplitude. Photoreceptor cell responses
(a-waves), which drive the b-waves, were equally affected (data not shown). Data are
expressed as mean ±SEM (n = 6-8 per condition; *, P<0.001)

To correlate the ERG findings with a behavioral measure of visual acuity,
we performed optokinetic response (OKR) tests to determine spatial frequency
(Fig. 2.4A) and contrast sensitivity (Fig. 2.4B) under photopic light conditions.
While spatial acuity and contrast sensitivity are influenced by both inner and
outer retina function, both measures have been shown to correlate with
photoreceptor cell function. Spatial acuity, which in rodents is low due to spatial
summation, can be observed after RPE [168] or photoreceptor cell damage
[169]. Likewise, loss of contrast sensitivity is a manifestation of photoreceptor cell
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loss in retinal degenerate mice (rd10) [170] or the Royal College of Surgeons rat
[171]. Spatial frequency threshold (spatial acuity) in WT mice after CE did not
differ from that of control animals exposed to room air (0.34±0.01 cyc/deg versus
0.37±0.01 cyc/deg; n.s.). Spatial frequency threshold was slightly lower in CFB −/−
control mice (0.31±0.01) than in WT controls (P<0.001); but just as in WT
animals, CFB −/− mice were unaffected by CE (0.33±0.00; P>0.05). Contrast
sensitivity on the other hand was affected by smoke inhalation. A robust
decrease in contrast sensitivity was observed for the WT smoke-exposed group
(7.16±0.37) compared to controls (18.34±1.00; P<0.01). As for the remaining
visual function tests, contrast sensitivity threshold was lower for CFB −/− control
mice (9.48±1.22) when compared to WT controls (P<0.001), but the levels were
unaffected by CE (10.78±0.61; P = 0.34).
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Figure 2.4 CE does not affect visual acuity, but impairs contrast sensitivity.
Optomotor responses were analyzed in WT and CFB −/− mice after exposure to 6
months of cigarette smoke (CE) or room air. (A) Visual acuity was measured by
identifying the spatial frequency threshold at a constant speed (12 deg/sec) and
contrast (100%). Spatial frequency thresholds were not affected by treatment, although
a genotype-dependent difference in visual acuity was identified (WT versus CFB −/− at
room air, P<0.001). (B) Contrast sensitivity was measured by taking the reciprocal of
the contrast threshold at a fixed spatial frequency (0.131 cyc/deg) and speed (12 deg/
sec). We previously determined that this spatial frequency falls within the range of
maximal contrast sensitivity for 9-month-old WT mice (data not shown). WT mice after
CE showed a significant reduction in contrast sensitivity compared to controls, while
AP-deficient mice remained unchanged. As for visual acuity, contrast sensitivity was
affected by genotype (P<0.001), with CFB −/− mice being significantly less sensitive.
Data are expressed as mean ±SEM (n = 3-9 per condition; *, P<0.01).
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Effect of AP Deficiency on Smoke-Induced Changes in Gene Expression
To gain further insight into how CE might be affecting visual function, QRTPCR was performed for a wide range of genes that fall into one of six categories:
photoreceptor cell function, complement activation, control of angiogenesis,
oxidative stress, autophagy, and mitochondrial function. With the exception of rod
and cone opsin gene levels, which were determined in retina samples, all other
genes reflected changes in the RPE/choroid fraction. The fold-difference between
room-air and smoke-exposed animals are plotted for WT (Fig. 2.5A) and CFB −/−
mice (Fig. 2.5B).
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Figure 2.5 Gene expression changes in ocular tissues between WT and CFB −/−
mice following CE. Analysis of marker gene expression in WT (A) and CFB −/− (B)
mice, using quantitative RT-PCR on cDNA generated from RPE/choroid/sclera fraction
and retina. Quantitative values were obtained by cycle number (Ct value), determining
the difference between the mean experimental and control (Actb) ΔCt values for
cigarette smoke (CE) versus room-air-exposed mice within each genotype (fold
difference). Candidates were examined from a number of categories including
photoreceptor cell function (Rho, Opn1sw, Opn1mw, Rpe65), complement activation
(C3, Cfb, Cfd, Cfh, Cd55, Cd59a), control of angiogenesis (Vegfa, Serpinf1), oxidative
stress (Hif1a, Cp), autophagy (Lyz1, Lamp2, Klc3), and mitochondrial function (Mfn1,
mt-Co1, Dnm1l, Ndufb8, Pfkfb1, Hmox1). Significant changes were identified in all six
categories for WT mice, suggesting decreased cone function and chromosphere
production, increased complement activation, the generation of a pro-angiogenic, and
oxidative environment with impaired repair processes (autophagy) and reduced energy
production under CE conditions. In comparison, gene expression was minimally
affected in CFB −/− animals. Data are expressed as mean ±SEM (n = 3 per condition; *,
P<0.05).
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In WT mice, CE significantly altered gene expression levels for genes
belonging to all six categories. First, since CE reduced ERG-amplitudes and
contrast sensitivity, levels of the genes encoding for the apoproteins of the
photopigments as well as the rate-limiting enzyme for the production of the
chromophore required for all pigments, RPE65, were examined. With the
exception of rhodopsin (Rho), all photoreceptor function genes were significantly
downregulated (short- and middle-wavelength cone opsins, Opn1sw; Opn1mw;
Rpe65). Second, CE has been shown to increase complement activation in the
mouse RPE [150]. Here, we find significant changes in gene expression in the
RPE/choroid following CE for complement genes, including increases in essential
components of the alternative and terminal complement pathway, CFB and C3;
and a decrease in complement inhibitors, CFH, CD55, and CD59. Third, smoking
is associated with edema, which in the RPE is controlled by two factors: the proangiogenic factor, VEGF (Vegfa), and the anti-angiogenic factor, pigment
epithelium-derived factor (PEDF [Serpinf1]) [172]. Vegfa was found to be
significantly elevated, whereas Serpinf1 showed a robust decrease of over 30fold. Fourth, smoking produces carbon monoxide, which binds to hemoglobin,
reducing oxygen availability, resulting in hypoxia. Here, we found that markers of
oxidative stress, including the hypoxia-inducible transcription factor, Hif1a, and
the ferroxidase enzyme, ceruloplasmin (Cp), were upregulated in the RPE/
choroid of smoke-exposed mice. Fifth, autophagy is a basic catabolic process
designed to remove damaged proteins and organelles expected to result from
CE. Autophagy genes in the RPE were downregulated under smoking conditions,
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with significant differences found for lysozyme 1 (Lyz1), lysosomal-associated
membrane protein 2 (Lamp2), and microtubule-associated protein 1 light chain 3
alpha (Map1lc3a). Sixth, an increase in mitochondrial number and decline in
mitochondrial function has been reported in response to tobacco smoke [173]. In
support of mitochondrial stress and biogenesis, we found a significant increase in
mitochondrial genes in the RPE/choroid affecting mitochondrial fission and fusion
(mitofusin 1, Mfn1; dynamin 1-like, Dnm1l); an increase in mitochondrial
respiratory proteins (NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8,
Ndufb8, mitochondrially encoded cytochrome c oxidase I, mt-Co1), as well as a
decrease in protective response gene heme oxygenase (decycling) 1 (Hmox1).
Finally, 6-phosphofructo-2-kinase/fructose-2,6-bi phosphatase1 (Pfkfb1), the rate
limiting enzyme in glycolysis, was found to be upregulated, potentially increasing
ATP production via glycolysis.
In CFB −/− mice, CE had minimal effects on retina and RPE/choroid gene
expression. No differences were observed in mRNA levels of genes involved in
photoreceptor cell function, complement activation or autophagy under CE
conditions when compared to controls. Significant changes were observed in
genes controlling angiogenesis (Vegfa, Serpinf1), oxidative stress (Hif1a) and
mitochondrial function (Mfn1, Dnm1l, Ndufb8, and Hmox1); however, the fold
changes were smaller than those in WT mice (5–84% of WT levels with a median
of 31%). Since functional differences were observed by ERG and OKR between
WT and CFB −/− mice, gene expression was compared between genotypes
without CE (Fig. 2.6). At 9 months-of-age, expression of opsin genes was
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increased, but levels of Rpe65 were significantly lower. In the absence of CFB,
levels of CFD were found to be significantly elevated, whereas angiogenesis and
autophagy genes were not altered in a consistent manner. Finally, changes in
mitochondrial gene expression were observed, with a reduction in Mfn1, Dnm1l,
Ndufb8, and Hmox1 along with an increase in Hif1a.

Figure 2.6 Differences in ocular gene expression between WT and CFB −/− mice
at baseline. Analysis of marker gene expression in WT and CFB −/− mice, using
quantitative RT-PCR on cDNA generated from RPE/choroid/sclera fraction and retina.
Quantitative values were obtained by cycle number (Ct value), determining the
difference between the mean experimental and control (Actb) ΔCt values for CFB −/−
versus WT mice exposed to room air (fold difference). Candidates were examined
from a number of categories including photoreceptor cell function (Rho, Opn1sw,
Opn1mw, Rpe65), complement activation (C3, Cfb, Cfd, Cfh, Cd55, Cd59a), control of
angiogenesis (Vegfa, Serpinf1), oxidative stress (Hif1a, Cp), autophagy (Lyz1, Lamp2,
Klc3), and mitochondrial function (Mfn1, mt-Co1, Dnm1l, Ndufb8, Pfkfb1, Hmox1).
Significant differences were identified in all six categories for CFB −/− mice, suggesting
increased cone function and reduced energy production compared to WT animals.
Data are expressed as mean ±SEM (n = 3 per condition; *, P<0.005; **, P<0.001).

Since most complement components are generated in the liver, and many
effects of complement activation are thought to be caused by systemic increases
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in complement activation, gene expression of C3, complement component 5
(C5), and complement component 9 (C9), as well as AP components CFB and
complement factor properdin (Cfp), were analyzed in livers from CE mice. With
the exception of C9, gene expression of all other components was significantly
elevated in WT mice (Fig. 2.7).

Figure 2.7 Gene expression changes in WT liver following CE. Analysis of
complement gene expression in WT mice, using quantitative RT-PCR on cDNA
generated from liver. Quantitative values were obtained by cycle number (Ct value),
determining the difference between the mean experimental and control (Actb) ΔCt
values for cigarette smoke (CE) versus room-air-exposed WT mice (fold difference).
Complement components C3 and C5 (hemolytic complement, Hc) were significantly
elevated along with AP activators Cfb and Cfp, whereas C9 remained unchanged.
Data are expressed as mean ±SEM (n = 3 per condition; *, P<0.001).

Effect of AP Deficiency on Smoke-Induced Histological Changes
Given the functional and behavioral deficits described above, animals
were examined using in vivo OCT imaging to determine the thickness of various
retinal layers (Fig. 2.8AB, EF). This was followed up with histological analyses by
light microscopy (Fig. 2.8CD, GH) and electron microscopy (see the following
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sections). Representative OCT images are presented for WT and CFB −/− mice
under CE and room-air conditions, together with corresponding retinal tissue
sections. There was noticeable thinning of the ONL and INL layer following CE in
C57BL/6J animals that was readily observed in both OCT and epon sections.
This change was not observed in CFB −/− mice.

Figure 2.8 Optical coherence tomography and histological sections from WT and CFB −/−
mice following CE. Posterior poles from WT (A-D) and AP-deficient (E-H) mice were analyzed
in vivo using OCT (A,B and E,F) and ex vivo using histology (C,D and G,H), comparing
cigarette smoke (CE) and control conditions. OCT measurements were taken ~0.5 mm from
the optic nerve head in the nasal quadrant. There is visible thinning of the ONL (red) and INL
(blue) in WT animals that is absent in CFB −/− mice. Light microscopy performed on epoxy
sections of central retina, derived from WT and CFB −/− animals, supports the thinning
observed in OCT images for WT mice exposed to smoke.

The OCT images were analyzed, using hyper-reflective bands to mark the
beginning and end of each retinal layer of interest, as previously described [174].
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We confirmed that there is a thinning of the ONL and INL in WT animals exposed
to smoke when compared to age-matched controls (ONL: 53.04±0.57 versus
47.84±0.08; INL: 24.18±0.27 versus 21.41±0.72; P<0.03). In contrast, the slight
reduction in ONL and INL thickness observed in CFB −/− mice was not found to
be statistically significant (ONL: 57.78±0.41 versus 51.95±0.64; INL: 24.29±0.49
versus 23.83±0.24; n.s.). ONL and INL thickness, however, did not differ between
genotypes when animals were raised in room air.
Ocular Localization of C3d After CE
To correlate ocular pathologies with complement activation, we analyzed
the localization of the complement activation product, C3d, a covalent cell
membrane-attached breakdown product of C3 using immunohistochemistry. C3d
was found to be deposited in RPE/BrM and choroid in WT mice exposed to
smoke (Fig. 2.9B), but not in control animals (Fig. 2.9A). No immunoreactive
material was found in the retina. Staining was attenuated in CFB −/− mice
exposed to smoke (Fig. 2.9D), whereas the CFB −/− mice raised in room air were
C3d negative (Fig. 2.9C).
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Figure 2.9 C3d deposition in eyes exposed to smoke. Localization of the complement
activation product, C3d, one of the C3 opsonins that binds covalently to (cell) membranes
was identified using immunohistochemistry, comparing WT (A,B) or CFB −/− mice (C,D)
exposed to room air (A,C) or cigarette smoke (CE) (B,D). Intense C3d immunoreactivity
(brown deposits) was seen in RPE/BrM and choroid in smoke-exposed WT mice when
compared to controls. In mice lacking the AP tick-over mechanism and amplification loop,
reduced staining was observed in RPE/BrM and choroid after CE, whereas those animals
exposed to room air demonstrated no immunoreactivity. Please note that in order to
perform labeling in the pigmented RPE and choroid, melanin was bleached, resulting in
faint pigmentation and revealing the nuclei of the RPE.

Lack of AP Abolishes Disruption of RPE-BrM Morphology Caused by CE
In order to gain a better understanding of the ultrastructural deficits that
underlie our AMD model, we analyzed EMs based on a number of different
criteria. These include RPE cell morphology, BrM thickness, IS/OS length, and
Müller cell area. Representative EMs for WT mice (Fig. 2.10AB) and CFB −/−
mice (Fig. 2.10CD) under control and CE conditions were depicted. BrM is a
pentalaminar structure, consisting of the basement membrane of the RPE, the
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inner collagenous zone, the middle elastic layer, the outer collagenous zone, and
the basement membrane of the choriocapillaris. Overall, BrM was remarkably
thicker in smoke-exposed WT animals when compared to controls raised in room
air. The typical pentalaminar structure of BrM was in disarray because the MEL
can no longer be distinguished in the smoke condition. Also, note the large
deposits in the outer collagenous layer (OCL; asterisks) in BrM that are absent in
the controls. These deposits were associated with lower fenestration density
(arrows) in the choriocapillaris. These fenestrations are responsible for shuttling
nutrients and waste across BrM between the RPE and choroid. In comparison,
fenestrations were dispersed evenly along the choriocapillaris in control animals.
Finally, mitochondria (insets) appeared to display a damaged phenotype under
smoke conditions. The outer membrane was not clearly defined and the cristae
appeared disorganized. In comparison, CFB −/− mice displayed none of the
smoke-induced distortions in RPE morphology that were identified in the WT
animals. BrM was found to remain intact, exhibiting the identifiable 5 layers,
without any apparent thickening. There were no deposits found in BrM and
fenestrations remained evenly spaced in the choriocapillaris. Lastly, mitochondria
appeared unchanged, displaying clear outer membranes with organized cristae.
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Figure 2.10 Ultrastructural changes in WT and CFB −/− mice following CE. Electron
micrographs of the RPE/BrM/choriocapillaris complex (RPE/BrM/CC) obtained from WT and
CFB −/− mice exposed to 6 months of cigarette smoke (CE) or room air were compared. (A) In
a WT animal raised in room air, BrM exhibits an organized pentalaminar structure, consisting
of RPE-BM, RPE basement membrane; ICL, inner collagenous layer; MEL, middle elastic
layer; OCL, outer collagenous layer; CC-BM, choriocapillaris basement membrane; and the
choriocapillaris endothelium has fenestrations along the entire membrane. (B) The RPE/BrM/
CC in a WT animal exposed to smoke exhibits pathological changes. BrM is disorganized,
losing its pentalaminar structure, and large deposits are present within the OCL. Note the
presence of choriocapillaris fenestrations (arrowheads) overlying BrM of normal thickness, but
fenestration loss and/or endothelial cell thickening adjacent to OCL deposits (asterisks). (C)
The RPE/BrM/CC is not affected by the elimination of CFB, but is preserved in CFB −/− mice
exposed to smoke inhalation (D). Insets highlight the morphological features of mitochondria
with degraded outer membranes and disorganized cristae in WT mice exposed to smoke and
normal appearance in the other three samples.
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EM results were quantified for the criteria listed above (Table 2.2) focusing
on aspects of energy metabolism in the RPE (mitochondria and BL-infoldings),
nutrient and waste transport (thickness of BrM) and photoreceptor function
(photoreceptor OS width and size of cell body). RPE cell morphology was
drastically altered in WT mice exposed to smoke. Mitochondria were found to be
significantly larger in C57BL/6J smoke-exposed animals compared to controls
(P<0.04), and made up a larger percentage of the total RPE cell area (P<0.05).
Both of these criteria remained unchanged after CE in CFB −/− animals. The total
number of mitochondria remained unchanged in both genotypes. Interestingly,
we also observed a treatment-dependent percent volume reduction of the BLinfoldings under smoking conditions for both genotypes (P<0.02). A robust
thickening of BrM was observed in WT mice exposed to smoke (P<0.05) that was
absent in CFB −/− mice. Finally, we determined the average width of the rod
photoreceptor OS and the area in the ONL occupied by photoreceptor cell
bodies. WT mice had significantly thinner rod OS following CE (P<0.05), and
exhibited photoreceptor hypertrophy and/or Müller cell atrophy when compared
to controls (P<0.02). In comparison, CFB −/− photoreceptor OS width and cell
body size was unaffected regardless of treatment.
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Table 2.2. Quantification of morphological structures from WT and CFB −/− mice following
CE. All area and length/width measurements are expressed in µm2 and µm, respectively. MITO,
mitochondria; BrM, Bruch’s membrane; ICL, inner collagenous layer; BL, basal laminar infoldings;
OS, outer segment. Data are expressed as mean ±SEM (n=4-6 per group; ✝, P<0.05; ✝✝,
P<0.01).

Criteria

WT
Control

WT Smoke

CFB -/Control

CFB -/- Smoke

MITO Number

31.66±2.17

32.50±2.44

31.25±3.13

33.05±1.67

MITO Area

29.94±1.95

40.21±3.75	
  ✝

33.88±2.08

33.86±1.05

BrM ICL Thickness

0.15±0.01

0.18±0.01 ✝

0.15±0.02

0.12±0.00

BL % Area

75.28±1.07

67.17±2.02 ✝ 72.04±1.64

63.88±1.14 ✝✝

OS Width

1.61±0.07

1.35±0.08 ✝

1.46±0.08

Müller Cell % Area

27.85±1.42

21.46±1.27 ✝ 22.73±1.25

1.53±0.03

23.39±1.21

Mitochondrial Relocalization Following CE is Absent in AP Deficient
Animals
Organelles in the RPE are distributed throughout the cell in a unique
fashion: that is, mitochondria are localized along the basal and basolateral
membranes, whereas melanocytes are localized predominantly along the apical
surface. Mislocalization of organelles has been recognized as a hallmark of
damaged RPE cells [175]. After 6 months of CE, melanocyte distribution was
found to be unaltered in both genotypes (data not shown). The mitochondrial
distribution profile for WT control mice confirmed that mitochondria are localized
along the basal (33.2±2.7%) and basolateral (40.9±2.7%) sectors of RPE cells
(Fig. 2.11A), whereas the central and apical sectors contain only 19.1±1.8% and
6.7±1.0% of the mitochondrial population, respectively. Following 6 months of
CE, we noticed an apical shift of the mitochondria from the basal sector to the
central sector (26.3±4.2%, 27.5±4.2%, respectively; P<0.05) (Fig. 2.11B). The
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basolateral and apical zones did not differ from the controls. The distribution
profile for CFB −/− room-air controls exhibited a similar mitochondrial distribution
pattern as the C57BL/6J mice, with the majority of mitochondria sequestered in
the basal (38.9±1.4%) and basolateral (40.6±2.8%) sectors (Fig. 2.11C). The
central and apical zones were also similar, containing 14.0±2.3% and 6.4±0.9%
of the mitochondrial population, respectively. The apical shift observed in C57BL/
6J animals was absent in the CFB −/− mice (Fig. 2.11D) following 6 months of
smoke exposure. The percent distribution in smoke-exposed animals between
basal, central, apical, and basolateral zones did not differ from age-matched
room-air raised controls.
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Figure 2.11 Mitochondrial localization is altered after CE. Mitochondrial position was
determined from electron micrographs (depicted in Figure 2.10) by determining their centroid
coordinates as a percentage of the corresponding RPE length and thickness, respectively.
Each centroid was subsequently assigned to one of 4 bins (basolateral, basal, central, or
apical). (A) The normalized positions of mitochondria within RPE of WT animals exposed to
room air demonstrates that mitochondria are anchored predominantly along the basolateral
and basal walls of the RPE cells and are more sparse throughout the central and apical
portion (see text for more detail). (B) Cigarette smoke exposure (CE) affects the mitochondrial
distribution in WT animals, with mitochondria exhibiting an apical shift from the basal to central
compartment. (C) Mitochondrial distribution is not affected by genotype, with CFB −/− mice
raised under control conditions exhibiting a normal distribution profile. (D) Six months of CE
had no effect on mitochondrial distribution in CFB −/− animals.
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Discussion
The main results of the current study were as follows: (1) WT mice
exposed to long-term smoke inhalation exhibited functional (ERG) and behavioral
(OKR) deficits in retinal function; (2) alterations in gene regulation in pathways
involved in photoreceptor signal transduction, as well as a RPE cell metabolism,
complement activation, angiogenesis, and catabolism may underlie these
observed differences; (3) CE caused morphological changes in RPE-BrM that are
similar to those observed in AMD such as thickening of BrM, deposit formation in
BrM, loss of BL-infolding of the RPE and dislocation of mitochondria; (4) these
changes in RPE-BrM may result in impairment of photoreceptor cell integrity as
evidenced by retinal thickness changes in OCT and photoreceptor morphometric
analyses in electron microscopy; (5) CFB −/− animals appear to be protected from
almost all smoke-induced changes that were observed in WT animals.
Dry AMD is considered a progressive disease, resulting in the gradual loss
of vision. The earliest clinical hallmarks observable are either the appearance of
drusen above a critical size (≥63 µm) and/or pigmentary changes in the center of
the globe [133]. Drusen are deposits made up of proteinaceous and lipid debris,
and are located between the RPE and the ICL of BrM. Since alterations due to
dry AMD and the normal aging processes overlap, it is difficult to assign observed
alterations to one or the other. Additional changes that occur include the
progressive thickening of both the inner and outer collagenous layer of BrM,
including the development of inclusions in the collagenous and elastin layers of
BrM [176]. In areas of RPE damage, choriocapillaris alterations, including
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reduction in fenestration or dropout, have been observed [177]. These alterations
in the choriocapillaris may be the underlying reason for the impaired perfusion
recognized in AMD [178]. Thickening of BrM, seen when using fluorescein
angiography, has been postulated to act as a diffusion barrier between the
choroid and BrM in AMD patients [179], which is supported by the observation of
age- and lipid-related changes in permeability of BrM for macromolecules [180,
181]. Loss of photoreceptor function and structure is associated with dry AMD. In
particular, abnormalities in dark adaptation of both rods and cones [182], with
raised cone thresholds in the parafoveal region [183], have been observed. Loss
of function may be due to retinoid deficiency based on the changes in BrM
permeability. This hypothesis is supported by experiments conducted by Owsley
et al. [165], demonstrating rod-mediated dark adaptation can be improved by
high doses of oral retinol. However, dropout of photoreceptors has been reported
in dry AMD starting in the parafoveal region, affecting both rods and cones [184].
The only environmental agent unequivocally linked to AMD is cigarette
smoke [102], and epidemiological studies have linked smoking to the progression
of AMD [185]. The most likely target for toxicity is the RPE, presumably by
generating oxidative stress. Although the RPE is constantly exposed to toxic
oxygen intermediates, it has available effective defenses against oxidative
damage, including high amounts of anti-oxidants [186]. The RPE anti-oxidative
capability is reduced with age [187, 188], and exposure to cigarette smoke may
accelerate this normal age-related decline in RPE cell function.
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Dry AMD has long been associated with inflammation and the complement
cascade [138]. However, not until the association of SNPs in the AP inhibitor,
CFH, with AMD risk, did that idea gain traction [91-93, 135]. While there are other
SNPs in genes that belong to the complement cascade (reviewed in Hecker and
Edwards [189]), the strongest link is with CFH. Additional support linking CFH to
AMD comes from patients with membranoproliferative glomerulonephritis
(MPGN) type II, a disease associated with CFH mutations, who develop drusen
which are indistinguishable from those in AMD [190]. Smoke extract has been
shown to be able to activate the AP in vitro [82] and serum levels of complement
components are elevated in smokers [191]. In a previous mouse study, using a
comparable smoke exposure model, components of the complement pathway
were identified between RPE and choroid in smoke-exposed, but not control
animals [150]. Those components included the anaphylatoxin C3a, complement
component C5, the MAC, as well as CFH. Thus, it appears likely that an
increased activity in the AP, both systemically and locally, may mediate the AMDlike changes observed in the RPE/choroid and retina in animals exposed to
constant smoke.
Here, we examined the effects of long-term CE on retinal structure and
function in mice. Similar to AMD patients, we noticed a decrease in b-wave
amplitudes under both scotopic and photopic conditions in WT mice exposed to
smoke. In particular, under dark-adapted conditions, ERG amplitudes were
diminished at light intensities sufficient to stimulate both rods and cones
(mesopic range). In addition, contrast sensitivity under photopic conditions was
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reduced, while spatial acuity at maximum contrast was unaffected. The results of
the QRT-PCR analysis allowed us to investigate several possible hypotheses.
One scenario is that smoke exposure may reduce the amount of pigment
available to trigger the phototransduction cascade. Gene expression levels for
rhodopsin were found to be unaltered by smoke exposure whereas mRNA levels
for UV- and MWL-cone opsin were both reduced approximately 2-fold; correlating
with the functional results. A second potential reason for the reduction in function
is that smoking reduces the amount of the rate-limiting enzyme, RPE65, required
to generate the chromophore, 11-cis retinal. The QRT-PCR data revealed an
approximately 3-fold decrease in Rpe65 mRNA levels following CE, which if
translated into a 3-fold reduction in protein level would significantly impact
chromophore formation [192]. Taken together, these results suggest that both
cone apoprotein and chromophore production is reduced in smoke-exposed
animals, leading to the observed decline in visual function in mesopic and
photopic ranges. Future experiments are required to determine whether a
reduction in cone opsin gene expression translates into shorter cone OS, or a
drop-out in cones. However, the decrease in visual function following CE was
accompanied by a thinning of both the ONL and INL as determined by OCT.
Interestingly, in clinical studies, the thickness of the ONL has been shown to
highly correlate with visual acuity in patients diagnosed with dry AMD [193]. Here,
we cannot conclude that the thinning is due to cell loss; cell counts would need to
be completed to further support this hypothesis. An alternative interpretation in
light of the electron microscopy data, showing an apparent Müller cell atrophy
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(Table 2.2), might be that the cell bodies of the photoreceptors are equal in
number, but closer together, resulting in a thinner ONL.
A growing body of literature suggests that dysfunctional mitochondria may
lie at the core of AMD etiology [34, 35]. Feher et al. [36] have reported agerelated changes in mitochondrial morphology that are accentuated in AMD. Aged
RPE contain mitochondria that show membrane disorganization, a focal loss of
cristae, and disruption of their apical-basal alignment. Work by He and TombranTink [37] showed that cultured RPE cells from aged donor eyes contain large,
fused mitochondria that generate less ATP than those obtained from young
donors. Interestingly, exposing mice to smoke replicates many of the changes
seen in the mitochondria of aged RPE cells. We found that CE leads to
mitochondria that display a damaged phenotype, with fractured outer membranes
and disorganized cristae. In addition, mitochondria were found to be significantly
enlarged (Table 2.2). In support of the balance between mitochondrial fission and
fusion being tipped towards fusion, Mfn1 was found to be increased ~14-fold,
whereas the fission protein, Dnm1l, was only increased 3-fold in the RPE of
smoke-exposed animals. Since larger mitochondria need more mitochondrial
respiratory proteins, it was logical to find that Ndufb8 and mt-Co1 were both
upregulated 4-fold. Although mitochondrial respiration has not yet been
measured in RPE cells obtained from smoke-exposed mice, mitochondrial ATP
production is expected to be lower. In support of this hypothesis, we observed
that gene expression for Pfkfb1, the rate-limiting enzyme in glycolysis, was found
to be significantly increased. An increase in ATP production via glycolysis, an
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anaerobic redox reaction, is often observed under conditions of limited ATP
synthesis by oxidative phosphorylation such as oxidative stress (Warburg effect
[194]). Mitochondria are mobile organelles that tend to sequester in areas of high
metabolic demand [195]. However, they can also move in response to
physiological changes, which we observed in the mitochondrial distribution
analysis. Taken together, we hypothesize that an inability to power the cellular
machinery used to generate chromophore and shuttle nutrients and waste
between the RPE and choroid, a consequence of defective mitochondria, might
contribute to the visual defects that develop in the smoke-exposed animals.
In addition to these mitochondrial deficiencies in the RPE, we observed a
thickening of BrM and formation of outer collagenous deposits. These deposits
were similar to the ones found by Mettu et al., using long-term exposure of mice
to hydroquinone, an abundant oxidant in cigarette smoke, but differ in location
from deposits in dry AMD [164]. In addition, alterations in the choriocapillaris
such as a loss of fenestrations in areas opposing the large BrM deposits were
observed. These morphological alterations may impede the aforementioned
transport of nutrients and waste between the RPE and choroid, ultimately leading
to impairment of photoreceptor cell function and structure. It is unclear as to the
source of the material accumulating in BrM. However, as all markers of
autophagy, the catabolic process responsible for removing damaged proteins
and organelles, were all significantly down-regulated in the RPE from smokeexposed animals. The increased amount of undigested material may get
exocytosed on the basal side of the RPE, resulting in deposit formation.
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Interestingly, Wang et al. [150] reported a decrease in lysosomal activity in a
culture model of aged RPE cells, and suggested that “the release of intracellular
proteins via exosomes by the aged RPE may contribute to the formation of
drusen.”
As indicated above, smoke exposure has been shown to be associated
with an increase in complement activation in human patients [191], an increase in
the risk for AMD [102], and an increase in complement deposition in the mouse
eye [150]. Here, we found complement C3d deposition on the basal side of the
RPE, indicating complement activation. Furthermore, we demonstrated increased
complement gene expression for C3 and Cfb, a significant decrease in the
membrane-bound and fluid phase inhibitors (CD55, CD59, and CFH) in the RPE,
as well as increased expression of AP complement proteins, C3 and C5 in the
liver. Most importantly, we found that the great majority of the functional and
structural alterations triggered by CE were absent in mice that lack the AP of
complement activation. These mice have a functional CP and LP, but lack the
tick-over process of spontaneous AP activation, as well as the AP amplification
loop. Our observations in CFB −/− mice can be paralleled by data from patients
with the CFB protective (R32Q) and CFH risk (Y402H) alleles. The R32Q allele,
which results in a CFB with less activity [142], is correlated with reduced drusen
size and total drusen area [143]. Likewise, the Y402H allele, which binds less
effectively to malondialdehyde epitopes and oxidized phospholipids (generated
by oxidative stress [125, 196]), is correlated with the size of peripheral drusen
and increases in reticular pigment [140, 141]. While both the human and our
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mouse data presented here suggest that increased AP activation is mediating
structural damage in RPE/BrM, a contribution of altered gene expression and
hence altered cellular homeostasis generated by R32Q, Y402H, or the lack of
CFB (Fig. 2.6) cannot be excluded. Complement effector systems are capable of
inducing inflammation, driving direct cell injury, and bridging the innate and
adaptive immune system through the interaction of complement opsonins and
anaphylotoxins. The precise mechanisms of complement-mediated injury herein
is difficult to determine, and further studies need to be conducted to investigate
the contributions of upstream and downstream components of the complement
cascade on smoke-induced pathologies. To date, the presence of C3 activation
fragments and MAC deposition in CE mice, together with the noted amelioration
of disease in CE CFB −/− mice supports the hypothesis that AP-mediated
activation of the complement system plays a role in CE-induced AMD pathology,
through complement-mediated effector mechanisms. However, a clear and sole
contribution of the MAC cannot be ascertained, given that complement opsonins
and anaphylatoxins can promote inflammation, cytokine release, and bridge
adaptive immune responses that may progress AMD pathology independent of
direct complement-mediated lysis. Finally, our group has generated a novel
recombinant form of the AP inhibitory protein, CR2-FH, consisting of the APinhibitory domain of mouse CFH, linked to a CR2 targeting fragment that binds
complement activation products. CR2-FH has been used successfully to inhibit
mouse choroidal neovascularization, a process requiring AP activation [81]. It
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would be of great interest to test this novel therapeutic to determine if smokeinduced retinal damage is preventable and/or reversible.
Taken together, there is growing evidence linking oxidative stress and
smoking, as well as complement activation to the development and progression
of AMD. Our data provided here show that CE in mice leads to functional and
morphological defects in the retina, RPE, BrM, and choriocapillaris, also seen in
patients with dry AMD. Our experiments, utilizing mice that lack the AP of
complement activation, provide the first direct evidence that complement
activation is required for these functional and structural alterations to occur, and
suggest that these morphological alterations may be amenable to anticomplement-based therapies.
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CHAPTER 3
A TARGETED INHIBITOR OF THE ALTERNATIVE PATHWAY REVERSES
SMOKE-INDUCED OCULAR INJURY
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Introduction
AMD is one of the leading causes of irreversible blindness among the
elderly in developed countries and is projected to affect 196 million people by
2020 [1]. AMD is a progressive, degenerative disease of the retina that results in
central vision loss caused by the degeneration of photoreceptor cells. This lateonset maculopathy can be diagnosed in two forms: atrophic, “dry”; or
neovascular, “wet” [133]. The atrophic form of the disease is marked by the
formation of yellow, lipoprotein deposits known as drusen (≥63 µm in size) in the
subretinal space between BrM and the RPE. The neovascular form is
characterized by the proliferation of choroidal blood vessels through BrM into the
subretinal space. These fragile vessels leak blood and proteins into the
subretinal or sub-RPE space [134], leading to retinal detachment followed by
photoreceptor cell death. Patients can develop either form of the disease;
however, the atrophic form is most common making up 90 percent of all cases
[2].
AMD is a multiplex disease that is influenced by genetic and
environmental factors. Many of the main genetic risk factors are polymorphisms
occurring in complement genes, a system whose role spans clearance of
pathogens from an organism to mediating the induction and expansion of
inflammatory injury. These genes include the AP inhibitor CFH, AP activator CFB,
complement component C2, and terminal pathway component C3. Perhaps the
most well-known of these is the Y402H SNP in the gene encoding CFH. Risk
variants of the Y402H SNP have been associated with increased levels of

73

granulocyte macrophage colony-stimulating factor in the vitreous and an
accumulation of choroidal macrophages, suggesting that a dysregulation of the
proinflammatory cytokines locally in the eye may underlie disease pathology
[197]. Increased levels of inflammation may be caused by poor binding of the
402H variants of factor H-like protein and CFH to BrM due to an impaired ability
to bind heparan sulphate [198, 199]. Furthermore, the effect of ranibizumab, a
common anti-angiogenic used to treat AMD, has been shown to be more or less
effective based on the Y402H allele patients express [200].
Cigarette smoke is the most significant environmental factor contributing
to AMD with an estimated risk increase of 2- to 4-fold [201]. Smoking promotes
the progression of AMD from the atrophic to neovascular form [56], which may
occur up to 10 years earlier in smokers compared to non-smokers [53]. However,
cessation has been shown to decrease the risk of developing AMD and the
progression to CNV [148]. The exact mechanisms responsible for smokers’
susceptibility to AMD is unknown, due in part to the massive number of
constituents in cigarette smoke, and there are likely a large number of
contributing factors involved. Both cigarette smoke and hydroquinone (HQ), a
component of cigarette smoke, induces oxidative damage and apoptosis in
human RPE cells [151]. HQ also downregulates pro-inflammatory monocyte
chemoattractant protein-1 and upregulates VEGF in RPE cells, suggesting that
incomplete clearance of pro-inflammatory debris coupled with increased
angiogenesis may promote drusen formation and progression to CNV in AMD
patients [71]. Finally, smoke extract has been shown to directly activate C3 [82]
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and trigger complement-dependent endoplasmic reticulum stress and lipid
deposition in ARPE-19 cells [126], providing a clear link between smoking and
complement activation.
Previous studies have shown that mice exposed to second hand cigarette
smoke over a long period of time exhibit activation of the terminal pathway of the
complement system in the RPE and choroid, concomitant with damage to the
RPE and photoreceptors [66, 70, 150-152]. We followed up on these findings by
investigating the effects of long-term CE in WT mice or mice lacking a functional
AP (CFB KO). CE in WT mice resulted in functional (decrease in rod and cone
ERG amplitudes), behavioral (decrease in cone-dependent contrast sensitivity),
molecular (altered gene expression in the RPE and photoreceptors), and
morphological (increase in mitochondrial size in the RPE, thickening of BrM)
impairment, while CFB KO mice were protected from developing any CEmediated alterations [202]. The purpose of this paper is to build on these findings
by determining whether the detrimental effects caused by chronic CE are
reversible following treatment with a novel AP inhibitor (CR2-FH). We
hypothesized that WT mice would recover from smoke-induced deficits based on
previous studies from our lab that have demonstrated efficacy for CR2-FH in
ameliorating laser-induced choroidal neovascularization, reducing RPE injury and
angiogenesis in mouse models of AMD [81, 203, 204], as well as preventing
smoke-induced complement activation and lipid deposition in ARPE-19 cells
[126].
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Materials and Methods
Animals
C57BL/6 mice were purchased (Jackson laboratory, Bar Harbor, ME)
[153], and we previously confirmed that these mice were negative for the RD8
locus [202]. Animals were housed under a 12:12 h, light:dark cycle with access to
food and water ad libitum.
For tail-vein injections, the vein was vasodilated by heat, a 25-gauge
needle was inserted, and a 100 µL volume was injected (250 µg CR2-fH in PBS
or PBS only). Dosing and treatment schedules are outlined in the Results
section. All experiments were approved by the Medical University of South
Carolina Institutional Animal Care and Use Committee and performed in
accordance with the Association for Research in Vision and Ophthalmology
statement for the use of animals in ophthalmic and vision research.
Exposure to Cigarette Smoke
Eight-week-old C57BL/6J male mice were divided into three groups (n = 6
per group). The control group was kept in a filtered air environment, and the two
experimental groups were subjected to cigarette smoke. CE was carried out (5
hours per day, 5 days per week) by burning 3R4F reference cigarettes (University
of Kentucky, Louisville, Kentucky, USA) using a smoking machine (Model TE-10;
Teague Enterprises) for 6 months. The average concentration of total suspended
particulates was 130 mg/m3 and was monitored twice daily.
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Plasmid Construction, Expression, and Purification of CR2-FH
Expression plasmids for the generation of CR2-FH were prepared as
previously described [81]. Briefly, the sequence encoding the four N-terminal
SCRs of mouse CR2 (residues 1-257 of mature protein; RefSeq NM 00758) was
linked to the sequence encoding the 5 N-terminal SCRs of mouse CFH (residues
1-303 of mature protein; RefSeq NM 009888) with a (G4S)2 linker. The expression
plasmid was the previously described PBM vector with a C5 signal peptide
sequence [205]. Final plasmid constructs were transfected into Chinese hamster
ovary cells with transfection reagent (FuGene HD; Roche Applied Science,
Indianapolis, IN) according to the manufacturer instructions, and protein
expression was quantified by ELISA and dot blot analysis. For protein
purification,Chinese hamster ovary cells expressing CR2-FH were cultured in
flasks (375 cm2), and culture supernatant was centrifuged at 2000g for 20
minutes, then filtered through a 0.22-µm filter. CR2-FH was purified from the
filtered supernatant by anti–mouse CR2 (mAb 7G6) affinity chromatography, as
previously described [205]. Detailed in vitro characterization of the fusion protein
demonstrating AP specific activity has been reported [206].
Optokinetic Response Test
Visual acuity and contrast sensitivity of mice were measured by observing
their optomotor responses to moving sine-wave gratings (OptoMotry) as
previously described [155]. Mice reflexively respond to rotating vertical gratings
by moving their head in the direction of grating rotation. To observe these
movements, mice were placed individually on the central elevated pedestal

77

surrounded by a square array of computer monitors that display stimulus
gratings. Mice were monitored via an overhead closed-circuit TV camera that
allowed the observer to view only the central platform and not the rotating
grating. Mice were allowed to adjust to the chamber for 2 min with the monitors
displaying a 50% gray uniform field prior to testing, and monitors returned to a
homogenous gray between trials. All tests were conducted under photopic
conditions with a mean luminance of 52 cd m−2. Visual acuity was measured by
finding the spatial frequency threshold of each animal at a constant speed (12
deg/s) and contrast (100%) with a staircase procedure that systematically
increased the spatial frequency of the grating until the animal no longer exhibited
detectable responses. Contrast sensitivity was determined by taking the
reciprocal of the contrast threshold at a fixed spatial frequency (0.131 cyc/deg)
and speed (12 deg/s). It has previously been determined that this spatial
frequency falls within the range of maximal contrast sensitivity for 9-month-old
C57BL/6J mice (data not shown). Contrast of the pattern was decreased
systematically in a staircase manner until the animal stopped responding.
Quantitative RT-PCR
RPE/choroid and retina fractions were isolated from control and smokeexposed animals and stored at −80°C until they were used. QRT-PCR analyses
were performed as previously described in detail [156]. In short, real-time PCR
analyses were performed in triplicate in a GeneAmp® 5700 Sequence Detection
System (Applied Biosystems) using standard cycling conditions. Quantitative
values were obtained by the cycle number, normalizing genes of interest to β-
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actin, and determining fold difference between room air and CE within
genotypes. Fold difference values were compared using Z-test analyses,
accepting a significance of P<0.05. See Table 2.1 for a full list of primers used for
QRT-PCR.
Tissue Preparation
The eyes were enucleated, and a slit was cut into the cornea to allow for
rapid influx of fixative. Eyes were fixed overnight in 2.5% glutaraldehyde, 1%
formaldehyde, 3% sucrose, and 1 mM MgSO4 in 0.1 M cacodylate buffer, pH 7.4.
The eyes were then dissected and small central portions were osmicated for 60
minutes in 0.5% OsO4 in 0.1 M cacodylate buffer, processed in maleate buffer for
en bloc staining with uranyl acetate, dehydrated in graded ethanols, and
processed for resin embedding as in [157]. Serial sections were cut at 90 nm on
a Leica Ultramicrotome onto carbon-coated Formvar® films supported by nickel
slot-grids.
Ultrastructural Analysis
EMs were captured using a JEOL JEM 1400 transmission electron
microscope using SerialEM software to automate image capture overnight with
1200–1500 images captured per section, yielding datasets that were then
processed with the NCR Toolset [158, 159] to generate image mosaics with
corrections for image aberrations induced by electron microscopy.
Electron microscopy images were evaluated using Adobe® Photoshop®
and ImageJ software. For each animal, two RPE cells were outlined using the
apical processes and the basal lamina (thickness) as well as the basolateral
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walls (length) as borders. A masking-layer for all mitochondria present within an
RPE cell was created to calculate average mitochondrial number and size. BrM
thickness was determined by analyzing ~200 µm sections of BrM. A masking
layer was created over segments of BrM, using choroidal intercapillary pillars and
the basement membrane of the RPE and CC as boundaries. The area of the
masking layer was divided by the length of each segment to determine an
average BrM thickness for each segment. We then calculated a weighted
thickness average based on the percentage length of each segment versus the
entire ~200 µm section being analyzed. Finally, we determined average BrM
thickness by summing weighted averages for each section. The number of OCL
deposits was calculated along a ~200 µm section of BrM. An ‘OCL deposit’ was
defined as the presence of any discrete focal nodule of homogenous material of
intermediate electron density between the OCL of BrM and the basement
membrane of the CC. ONL thickness was determined by averaging
measurements taken at five arbitrary points along a ~200 µm section of retinal
tissue, using the outer plexiform layer (upper) and outer limiting membrane
(lower) as boundaries. Müller cell percent area was determined by subtracting
the area occupied by the rod/cone somas in a ~600 µm2 area of the ONL and
dividing by the total area analyzed; using the same masking technique as
described from BrM thickness analysis. Photoreceptor cell counts were
determined by counting the number of cell bodies present within a ~600 µm2 area
of the ONL.
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Mitochondrial distribution profiles were generated by performing a percent
normalization on the coordinates of centroids for all mitochondria with respect to
the length/width of the RPE cell they were imaged from. After plotting the data,
we assigned each mitochondrion to one of 4 bins as follows: basolateral (x-value
<0.20 or x-value >0.80), basal (0.20≤ x-value ≤0.80 and y-value <0.33), central
(0.20≤ x-value ≤0.80 and 0.33≤ y-value <0.66), and apical (0.20≤ x-value ≤0.80
and 0.66≤ y-value <1). Significance values were based on the percentage of
mitochondria that fall into each bin.
Statistics
For data consisting of multiple groups, repeated measures ANOVA
followed by the Fisher post hoc test (P<0.05) was used; single comparisons were
analyzed using the Student t-test assuming equal variance (P<0.05; Statview;
SAS Institute, Inc.). Fold changes in QRT-PCR experiments were analyzed using
a Z-test (P<0.05).
Results
Effect of CR2-FH Treatment on Smoke-Induced Impairment of Visual
Function
There is ample evidence that morphological and cellular alterations lead to
vision loss or impairment in dry AMD. Dry AMD in patients is associated with
drusen formation and a thickening of BrM that can eventually lead to
photoreceptor degeneration [162, 163, 207]. Amyloid-beta, a component of
drusen, reduces mitochondrial redox potential and increases the production of
reactive oxygen species in RPE cells [208], resulting in a metabolic imbalance
and contributing to geographic atrophy. Structural changes to BrM can lead to
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impaired exchange of waste and nutrients between the RPE and choroid [164] as
well as a reduction in the generation and delivery of 11-cis-retinal, a vitamin-Abased chromophore essential for proper visual function, to photoreceptor outer
segments [165]. These AMD-associated pathologies manifest as reductions in
visual function, which can be measured by changes in visual acuity and contrast
sensitivity. These pathological alterations are associated with increased
deposition of activation products of the complement system in drusen and BrM
[138, 209] and reduced expression levels and altered distribution of complement
inhibitors [78, 79, 210]. There seems to be a consensus that complement
activation is involved in promoting drusen formation and BrM thickening;
however, it is unclear whether continued complement activation is required to
maintain these structures. Or in other words, can complement inhibitors be used
to restore ocular health?
To mimic complement-dependent RPE-BrM changes and visual function
loss seen in dry AMD, we used a smoke inhalation model in mice (reviewed in
[211]). After 6 months of CE, we measured visual function in animals via OKR
testing before they were returned to room air and randomly divided into two
experimental groups, PBS and CR2-FH. The inhibitor, CR2-FH, has both a
targeting domain (SCRs 1-4 of CR2) and the complement inhibitory domain of
CFH. CR2 acts as a targeting moiety, since it binds to cell-bound cleavage
fragments of C3 present at sites of complement activation [212]. Animals were
treated once a week (250 µg/animal in 100 µL of PBS) for three months. We
performed OKR tests to determine the effects of CR2-FH on visual function.
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Spatial frequency (Fig. 3.1A) and contrast sensitivity (Fig. 3.1B) were measured
under photopic light conditions. Both measures of visual function are influenced
by inner and outer retina function and correlate with photoreceptor cell function
[213]. A reduction in spatial frequency threshold (spatial acuity) can be observed
in rodents following RPE [168] or photoreceptor cell loss [169], and contrast
sensitivity correlates with photoreceptor cell viability as observed in retinal
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Figure 3.1 Post treatment with CR2-FH reverses smoke-induced impairment of
contrast sensitivity. Optomotor responses were analyzed in WT mice after 6 months
of cigarette smoke exposure (CE) or room air followed by 3 months of treatment with
nothing, PBS, or CR2-FH. (A) Visual acuity was measured by identifying the spatial
frequency threshold at a constant speed (12 deg/sec) and contrast (100%). Spatial
frequency thresholds were not affected by treatment. (B) Contrast sensitivity was
measured by taking the reciprocal of the contrast threshold at a fixed spatial frequency
(0.131 cyc/deg) and speed (12 deg/sec). We previously determined that this spatial
frequency falls within the range of maximal contrast sensitivity for 9-month-old WT
mice (data not shown). WT mice after CE showed a significant reduction in contrast
sensitivity compared to controls. However, smoke-exposed mice treated with CR2-FH
showed a contrast sensitivity that is similar to room air controls and significantly higher
than PBS-treated mice following CE. Data are expressed as mean ±SEM (n = 4-6 per
condition; *, P<0.01).
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degenerate mice (rd10) [170] and the Royal College of Surgeons rat [171].
Spatial acuity in WT mice after CE (pre-treatment) did not differ from that
of control animals exposed to room air (Smoke+PBS 0.31±0.01 versus
0.31±0.01; P=0.65, Smoke+CR2-FH 0.32±0.01; P=0.80) Spatial acuity in CE
mice followed by PBS treatment did not differ from age-matched room air
controls (0.30±0.01 cyc/deg versus 0.31±0.02 cyc/deg; P=0.53). Likewise,
treatment of CE mice for 3 months with CR2-FH had no effect on spatial acuity
when compared to vehicle controls (0.33±0.02 cyc/deg; P=0.55). There were also
no significant pre-post treatment differences in spatial acuity for any group.
Previously, we have shown that contrast sensitivity is significantly reduced by
cigarette smoke exposure [202]. Here, we confirmed these findings showing that
WT mice following CE (pre-treatment) exhibit a significant decrease in contrast
sensitivity compared to room air controls (Smoke+PBS 4.57±0.97 versus
10.14±0.41; P<0.01, Smoke+CR2-FH 5.78±0.52; P<0.01). Furthermore, we
found that CE mice treated with PBS for 3 months still exhibit a robust decrease
in contrast sensitivity (4.89±1.14) compared to room air controls (9.97±0.53;
P<0.01). Importantly, contrast sensitivity threshold in CE mice treated with CR2FH recovered to levels similar to those of non-smoked, age-matched controls
(9.14±0.39; P=0.29), levels which are dramatically higher than those of smokedexposed, vehicle-treated animals (P<0.05). There were no significant pre-post
treatment differences for room air controls (P=0.80) or CE mice treated with PBS
(P=0.84), however CE mice treated with CR2-FH showed a significant increase
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in contrast sensitivity following treatment (P<0.01), suggesting that CR2-FH was
able to reverse smoke-induced deficits in contrast sensitivity.
Effect of CR2-FH Treatment on Smoke-Induced Changes in Gene
Expression
To further understand how CR2-FH treatment following CE may be
affecting visual function, QRT-PCR was performed for a wide range of genes that
fall into one of six categories: photoreceptor cell function, complement activation,
control of angiogenesis, oxidative stress, autophagy, and mitochondrial function.
With the exception of rod and cone opsin gene levels, which were determined in
retina samples, all other genes reflected changes in the RPE/choroid fraction.
The fold-difference between room-air and smoke-exposed animals following
treatment with PBS or CR2-FH are plotted (Fig. 3.2).
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Figure 3.2 Gene expression changes in ocular tissues following treatment with CR2-FH
in smoke-exposed mice. Analysis of marker gene expression in smoke-exposed mice
following treatment with PBS or CR2-FH, using quantitative RT-PCR on cDNA generated from
RPE/choroid/sclera fraction and retina. Quantitative values were obtained by cycle number
(Ct value), determining the difference between the mean experimental and control (Actb) ΔCt
values for PBS- and CR2-FH-treated mice following cigarette smoke exposure (CE) versus
room-air-exposed mice (fold difference). Candidates were examined from a number of
categories including photoreceptor cell function (Rho, Opn1sw, Opn1mw, Rpe65),
complement activation (C3, Cfb, Cfd, Cfh, Cd55, Cd59a), control of angiogenesis (Vegfa,
Serpinf1), oxidative stress (Hif1a, Cp), autophagy (Lyz1, Lamp2, Klc3), and mitochondrial
function (Mfn1, mt-Co1, Dnm1l, Ndufb8, Pfkfb1, Hmox1). Significant changes were identified
in several categories for CR2-FH-treated mice, suggesting decreased complement activation
and enhanced energy production. Statistics represent comparisons between PBS- and CR2FH animals following CE. Data are expressed as mean ±SEM (n = 3 per condition; *, P<0.01;
** P<0.001; ***, P<0.0001).

Changes in gene expression following smoke-exposure for genes
belonging to all six aforementioned categories have been previously shown
[202]. Here, we asked whether these genes play a role in the recovery of visual
function in CE mice treated with CR2-FH. Since CR2-FH treatment increased
contrast sensitivity after CE, we examined levels of genes encoding for the
apoproteins of the photopigments as well as the rate-limiting enzyme for the
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production of the chromophore required for all pigments, RPE65. However, no
differences were observed in mRNA levels of genes involved in photoreceptor
cell function. CE has been shown to increase complement activation in the
mouse RPE [150]. Here, we find that mice treated with PBS for 3 months
following CE still exhibit changes in gene expression in the RPE/choroid for
complement genes, including increases in essential components of the
alternative and terminal pathway, CFB, CFD, and C3; and decreases in
complement inhibitors, CD55 and CD59. Treatment with CR2-FH decreased the
expression of CFB and CFD by 30- and 60-fold, respectively. Significant
decreases in CFH, CD55, and CD59 expression likely represent compensatory
mechanisms caused by the introduction of an exogenous AP inhibitor. Although
CR2-FH treatment was associated with a significant decrease in the expression
of anti-angiogenic factor, PEDF (Serpinf1), compared to PBS-treated animals,
these levels were not different from room-air controls. Genes associated with
oxidative stress and autophagy were not altered in a significant manner, with the
exception of lysozyme 1 (Lyz1). A five-fold decrease in Lyz1 mRNA expression
was observed in CR2-FH-treated mice compared to PBS-treated animals.
Lysozyme has been shown to inhibit the haemolytic activity of serum complement
in a dose-dependent manner [214]. Therefore, this decrease in Lyz1 may be
reflect a compensatory downregulation related to enhanced complement
inhibition in CR2-FH-treated animals. An increase in mitochondrial number and
decline in mitochondrial function has been reported in response to tobacco
smoke [173]. In support of reducing mitochondrial stress and biogenesis, we
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found that treatment with CR2-FH resulted in a significant decrease in
mitochondrial genes in RPE/choroid affecting mitochondrial fission and fusion
(mitofusin 1, Mfn1; dynamin 1-like, Dnm1l) and an increase in protective
response gene heme oxygenase (decycling) 1 (Hmox1) when compared to PBStreated mice. However, 6-phosphofructo-2-kinase/fructose-2,6-biphosphate1
(Pfkfb1), the rate limiting enzyme in glycolysis, was found to be upregulated in
CR2-FH- versus PBS-treated animals, suggesting that ATP production via
glycolysis is still necessary to meet energy demands.
Post Treatment with CR2-FH Abolishes Morphological Distubances in RPEBrM Caused by CE
Loss in contrast sensitivity following smoke-exposure has previously been
shown to be associated with specific morphological alterations in RPE, BrM, and
Müller cells [202]. Here, we asked whether these same features play a role in the
recovery of visual function in CE mice treated with CR2-FH. We analyzed EMs
obtained from CR2-FH and PBS cohorts based on the following criteria: BrM
thickness, mitochondrial morphology, and Müller cell area. Representative EMs
for WT non-smoked controls (Fig. 3.3A), PBS-treated after CE (Fig. 3.3B), and
CR2-FH-treated after CE (Fig. 3.3C) were depicted. BrM is a pentalaminar
structure consisting of the basement membrane of the RPE, the inner
collagenous zone, the middle elastic layer, the outer collagenous zone, and the
basement membrane of the choriocapillaris. BrM is thicker in CE mice compared
to non-smoked controls. The pentalaminar structure of BrM was disrupted as
evidenced by an inconsistent MEL. Areas of BrM disorganization were especially
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prevalent near large deposits located in the outer collagenous layer (asterisks)
that are absent in controls. These deposits were associated with lower
fenestration density (arrows) in the choriocapillaris, which are responsible for
transferring nutrients and waste across BrM between the choroid and RPE. In
contrast, non-smoked controls maintained a high fenestration count along the
choriocapillaris with little to no outer collagenous deposits. Mitochondria (insets)
were significantly altered in CE animals, characterized by poorly defined outer
membranes and disorganized cristae. Room air controls displayed healthy
mitochondria with clearly defined outer membranes and organized cristae. These
results were consistent with previous findings from our lab obtained from animals
examined immediately following the completion of the 6 month CE period [202].
However, treatment with CR2-FH following CE reversed all smoke-induced
ultrastructural deficits. BrM appeared intact, exhibiting the full pentalaminar
structure, without any apparent thickening. Few deposits were found in BrM and
fenestrations were evenly distributed along the choriocapillaris. Likewise, the
mitochondrial phenotype also appeared to be healthy, as evidenced by a clear
outer membrane and organized cristae.
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Figure 3.3 CR2-FH rescues ultrastructural changes in WT mice following CE. Electron
micrographs of the RPE/BrM/choriocapillaris complex (RPE/BrM/CC) obtained from WT mice
after 6 months of cigarette smoke exposure (CE) or room air followed by 3 months of treatment
with nothing, PBS, or CR2-FH were compared. (A) In a WT animal raised in room air, BrM
exhibits an organized pentalaminar structure consisting of RPE basement membrane, inner
collagenous layer, middle elastic layer, outer collagenous layer (OCL), and choriocapillaris
basement membrane. The choriocapillaris endothelium has fenestrations (arrowheads) along
the entire membrane. (B) The RPE/BrM/CC in a WT animal following CE exhibits pathological
changes. BrM is disorganized, no longer showing a pentalaminar structure and large deposits
(asterisks) are present in the OCL. Notably, there is significant fenestration loss and/or
endothelial cell thickening adjacent to OCL deposits. (C) The RPE/BrM/CC is unaffected in WT
mice treated with CR2-FH following CE. Insets highlight the morphological features of
mitochondria with degraded outer membranes and disorganized cristae in WT mice exposed to
smoke (B), but normal appearance in room air controls (A) and WT mice treated with CR2-FH
following CE (C).

EM results were quantified for the aforementioned criteria (Table 3.1)
focusing on morphological correlates of energy metabolism in the RPE
(mitochondria), nutrient and waste transport (BrM thickness and outer
collagenous deposit count), and photoreceptor function (ONL thickness and
photoreceptor cell count). Mitochondria were found to be significantly larger in
CE mice compared to non-smoked controls (P<0.05) and made up a larger
percentage of total RPE cell area (P<0.05). Mitochondrial morphology completely
recovered during the 3 month period when treated with CR2-FH. The total
number of mitochondria remained unchanged between all three groups. We
observed a thickening of BrM in CE mice compared to room air controls, and BrM
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thickness was restored when treated with CR2-FH; however, this did not reach
statistical significance. CE triggers the formation of outer collagenous deposits in
BrM [202], which are maintained in CE mice treated with vehicle (P<0.01), but
removed in those treated with CR2-FH. Finally, we measured the thickness of the
ONL, the number of photoreceptor cell bodies in the ONL, and the area of the
ONL occupied by Müller cells. Smoke-exposed WT mice had a significantly
thinner ONL (P<0.05), which is due to Müller cell hypertrophy (P<0.01) rather
than loss of photoreceptors, as the number of nuclei in the ONL did not change
with smoking. In contrast, treatment with CR2-FH in animals following CE
restored the thickness of the ONL to normal levels (P<0.05); however, Müller cell
hypertrophy was still present (P<0.01). The number of photoreceptor cell bodies
in the ONL remained unchanged between all groups.
Table 3.1. Quantification of morphological structures from mice treated with CR2-FH
following CE. All area and thickness measurements are expressed in µm2 and µm, respectively.
MITO measurements refer to the number, area, and percentage of mitochondrial area occupied
per RPE cell. OCL Deposit Count reflects the number of deposits per mm. Müller Cell % Area
refers to the percentage of a 600 µm2 area of the ONL occupied by Müller cells. Photoreceptor
Cell Count reflects the number of cell bodies present in a 600 µm2 area of the ONL. MITO,
mitochondria; BrM, Bruch’s membrane; OCL, outer collagenous layer; ONL outer nuclear layer.
Data are expressed as mean ±SEM (n = 3-6 per group; ✝, P<0.05; ✝✝, P<0.01).

Criteria

NS Control

Smoke+PBS

Smoke+CR2-FH

MITO Number

26.92±1.23

30.00±1.53

30.25±1.64

MITO Area

42.68±2.27

54.62±2.48 ✝

45.01±1.21

MITO % Area

4.71±0.70

8.30±0.65 ✝

6.29±0.22

BrM Thickness

0.62±0.03

0.80±0.13

0.61±0.05

OCL Deposit Count

7.84±2.26

38.87±7.05 ✝✝

4.08±1.42

ONL Thickness

44.77±1.31

36.86±2.79 ✝

44.65±0.87

Photoreceptor Cell Count

38.60±0.93

39.00±1.16

38.00±0.95
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Criteria
Müller Cell % Area

NS Control
28.87±1.37

Smoke+PBS
18.33±1.41 ✝✝

Smoke+CR2-FH
21.90±1.67 ✝✝

Mitochondria in the RPE are distributed throughout the cell following
particular localization patterns. Typically, they align along the basal and
basolateral membranes under normal conditions. We have previously shown that
the mitochondrial distribution profile is disrupted following cigarette smoke
exposure [202]. Notably, there is an apical shift from the basal to central sector in
WT mice following CE. Here, we found that there were no significant differences
between groups in any of the four localization bins analyzed (Fig. 3.4).
Spontaneous restoration of mitochondrial relocalization during the 3 month
period following smoke exposure may be the reason we did not observe an
apical shift in CE mice.
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Figure 3.4 Mitochondrial localization is unchanged in CE mice after treatment.
Mitochondrial position was determined from electron micrographs (depicted in Figure 3.3) by
determining their centroid coordinates as a percentage of the corresponding RPE length and
thickness, respectively. Each centroid was subsequently assigned to one of 4 bins
(basolateral, basal, central, or apical). The normalized positions of mitochondria within RPE of
WT animals exposed to room air demonstrates that mitochondria are anchored predominantly
along the basolateral and basal walls of the RPE cells and are more sparse throughout the
central and apical portion (see text for more detail). Three months of treatment with PBS or
CR2-FH following cigarette exposure (CE) had no effect on mitochondrial distribution.

Discussion
Previously, we have shown that long-term cigarette smoke inhalation leads
to ocular pathology that is dependent on complement activation and requires the
AP [202]. These changes included deposit formation in BrM, mitochondrial
swelling and/or fusion in the RPE, a thinning of the ONL, and Müller cell
hypotrophy, which correlated with a reduction in contrast sensitivity as assessed
by OKR. Here, we showed that these structural and functional changes do not
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reverse upon cessation of smoking. Importantly, we showed that mice exposed to
6 months of cigarette smoke inhalation followed by 3 months of room air still
exhibited behavioral (OKR) deficits in retinal function; morphological changes in
RPE-BrM including deposit formation in BrM and mitochondrial swelling and/or
fusion; and changes in ONL thickness and Müller cell size. In contrast, mice that
were supplemented with the AP inhibitor CR2-FH during the 3 months of room air
showed a reversal or attenuation of all smoke-induced morphological changes
and a complete recovery of visual function.
Here, we confirmed and extended our previous data on retinal structure
and function in mice following long-term smoke exposure. In particular, we asked
whether structural and functional changes triggered by 6 months of CE are
reversible upon cessation of smoking. Previously, we showed that while spatial
acuity is retained in mice after 6 months of CE, contrast sensitivity is reduced by
~60%. Allowing mice to recover in room air only marginally affected contrast
sensitivity, as the threshold after 3 months was still suppressed by ~50%. Spatial
acuity, as previously shown, remained unchanged between groups. Similarly, the
thinning of the ONL observed after 6 months of smoke is retained after 3 months
of recovery, as is Müller cell atrophy, the presence of large numbers of OCL
deposits in BrM, and the increase in mitochondrial area. Interestingly, overall BrM
thickness after 3 months of room air was still increased in CE mice by ~30%;
however, this difference was no longer significant based on the large variability in
CE mice compared to controls. Finally, the percent volume reduction of BL-
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infoldings previously observed after 6 months of smoke, was no longer apparent
following recovery in 3 months of room air (data not shown).
Contrast sensitivity loss, particularly in the short wavelength channel, is
associated with early AMD [215]. Delayed rod-mediated dark adaptation rather
than visual acuity, low luminance acuity, and spatial contrast sensitivity can be
used as a tool to detect early AMD [216], suggesting that eyes with normal cell
counts, but thickened BrM and drusen formation, exhibit vision changes due to
the metabolic health of the cells rather than cell loss. On the other hand,
sustained visual acuity loss in AMD is most commonly associated with foveal
scarring, pigmentary abnormalities, and foveal GA [217], which are all common in
dry AMD. Müller cell hypotrophy has not yet been reported in AMD; however,
Müller cell hypotrophy, concomitant with increased GFAP expression, has been
found in stressed explanted neonatal rat retina [218]. These stressed Müller cells
might increase expression of cytokines and chemokines that contribute to the
inflammatory state of the retina, contributing to photoreceptor cell loss (e.g.
[219]). The formation of deposits in the OCL of BrM in CE mice are different in
localization from pathological structures in AMD. Drusen are found between BrM
and the RPE, reticular pseudodrusen are located internal to the RPE, BLamDs
are found between the RPE basement and plasma membranes, BLinDs are
found between the RPE basement membrane and the ICL of BrM [220].
Nevertheless, since the deposits in mice are positive for complement activation
products [202], they appear worth investigating in the context of complement
dependent ocular deposit formation. Previous reports have shown that RPE from
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aged subjects or those with advanced dry AMD contain progressively more
fragmented mitochondria that generate less ATP [37] and show membrane
disorganization and focal loss of cristae. It is important to note that healthy
mitochondria undergo constant fission and fusion to maintain a healthy
mitochondrial network. However, under stress conditions, mitochondria will
undergo hyperfusion, particularly during periods of starvation [221], followed by
rapid and extensive fission early in apoptosis [222].
Cigarette smoking is the leading environmental insult associated with AMD
[223]. The number of pack years of cigarette smokers has been directly linked to
the risk of developing geographic atrophy and CNV [148], two hallmark features
of atrophic and neovascular AMD respectively. Experimental evidence exists,
demonstrating how smoking may contribute to disease. For example, in RPE
cells, one of the main targets in atrophic AMD, short term cigarette smoke
exposure results in an increase in oxidative and endoplasmic reticulum stress, as
well as complement activation via the AP, which leads to lipid accumulation after
long term smoke exposure [224]. Likewise, the choroid appears to be a target of
smoking, as chronic cigarette smokers with atrophic AMD have a thinner choroid
compared to nonsmokers [225]. A less effective choroidal network along with a
thickening of BrM and drusen formation can result in decreased delivery and
clearance of nutrients/waste to and from the RPE. Finally, evidence suggests that
dysregulation of the VEGF/PEDF ratio may be implicated in the pathogenesis of
CNV in AMD [226]. Interestingly, nicotine, a primary constituent of cigarette
smoke, has been shown to increase the VEGF-to-PEDF ratio in the RPE through
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nicotinic acetylcholine receptor-mediated signaling pathways [227], thereby
promoting angiogenesis.
A link between smoking and complement activation in disease has long
been established, including emphysema [228], cardiovascular disease [229], and
age-related macular degeneration [223]. Likewise, inflammation and the
complement cascade have long been associated with dry AMD [138]. However,
this association was not solidified until SNPs in the AP inhibitor, CFH were linked
with AMD risk [91-93, 135]. Smoking is the single most prevalent, modifiable risk
factor for AMD [148] and increases the risk of developing AMD in CFH risk factor
subjects (402H) in an additive fashion [91-93]. Since smoking increases the
plasma concentration of complement components [230], and smoke extract
directly activates C3 [82], it is reasonable to assume that smoking and
complement activation contribute in an additive fashion to AMD pathology.
In patients, the question of whether smoke-induced pathology is reversible
has not yet been addressed. However, Neuner and colleages have posed a
similar question in the Muenster Aging and Retina Study [231]. The group
followed aged smokers and non-smokers without AMD over a median of 30.9
months and reported their adjusted risk ratios for incident AMD. Of the 9.6% of
subjects that progressed to AMD, the adjusted risk ratio in current versus never
smokers was 3.25 (95% confidence interval [1.50–7.06]), but was still
significantly elevated by 1.28 [0.70–2.33] in former smokers versus never
smokers.
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As a second question, we asked whether continued complement activation
was required to maintain the structural and functional deficits observed in smokeexposed mice, or whether reversal of damage could be observed upon
complement inhibition. Our group has generated a novel recombinant form of the
AP inhibitory protein, CR2-FH, consisting of the AP-inhibitory domain of mouse
CFH linked to a CR2 targeting fragment that binds membrane-bound
complement activation products. By comparison, CR2-FH is able to block C3
deposition on the zymosan at least 20-fold more effectively than endogenous
CFH [206]. CR2-FH has been shown to reduce complement activation,
inflammation, and injury to the colon in a model of chronic dextran sulphate
sodium-induced colitis [232], block the progression of both acute and chronic
autoimmune demyelinating disease in an experimental encephalomyelitis study
[233], and attenuate deficits associated with cerebral ischemia-reperfusion injury
[234]. CR2-FH has also been used to inhibit choroidal neovascularization, a
process requiring AP activation [81, 203] as well as smoke-induced lipid
deposition in cultured RPE cells [126]. However, no studies have been conducted
to test the efficacy of this AP inhibitory protein in a model of dry AMD, particularly
using a therapeutic rather than preventative paradigm. Here, we show the first
conclusive evidence that CR2-FH is effective in reducing or reversing smokeinduced ocular pathology which models elements of dry AMD.
We previously showed that preventing AP complement activation (CFB KO
mice) prevented the development of all CE-mediated structural and functional
alterations [202]. Here, we asked whether CR2-FH can accelerate the reversal of
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pathology when applied weekly. Remarkably, we found that smoke-induced
decreases in contrast sensitivity can be completely reversed following treatment
with CR2-FH. Functional improvement was found to correlate with an attenuation
of morphological differences in RPE-BrM. Not only did CR2-FH reverse the trend
towards a thicker BrM and increases in OCL deposit formation caused by CE, but
also reversed alterations in the choriocapillaris, including restoration of
fenestrations in areas of close proximity to OCL deposits. In addition, CR2-FH
was effective in reversing all mitochondrial impairments observed under smoke
conditions. Our data suggests that inhibition of the AP of complement is
paramount to reversing ocular smoke pathology, and CR2-FH appears to be a
potent inhibitor of this pathway. However, further experiments need to be
conducted to determine the therapeutic window, most effective dosage, and ideal
delivery modality for this AP inhibitor following chronic cigarette smoke exposure
or other complement-dependent AMD models. Our data supports some of the
findings of the Phase II clinical trial for lampalizumab [235], an anti-factor D
monoclonal antibody applied intravitreally. In this study, 129 patients with bilateral
GA were treated monthly with either 10 mg lampalizumab or vehicle. When
analyzed as a group at 18 months, lampalizumab-treated patients showed a
~20% reduction in the size of GA lesions (n.s.); whereas, a subgroup analysis
revealed that patients with a CFI mutation have a much greater response (~44%;
P<0.005) (summarized in [236]).
There is a growing body of evidence linking oxidative stress, cigarette
smoking, and complement activation to the development and progression of
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AMD. Our data provided here show that CE in mice causes behavioral and
morphological defects in the retina, RPE, BrM, and choriocapillaris, similar to
what is observed in patients with dry AMD. Our experiments, utilizing CR2-FH
administered to mice following CE, provide the first evidence that complementbased therapy is effective in treating smoke-induced ocular pathology, and
suggests that this line of therapy may be effective in treating dry AMD in humans.
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CHAPTER 4
SUMMARY AND CONCLUSIONS
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Discussion
AMD is a multifactorial disease that causes progressive impairment of
central vision, and is considered the leading cause of severe vision loss and
blindness in elderly Western populations. Genetic susceptibility, environmental
factors, and metabolic conditions all contribute to the clinical manifestation of the
disease. AMD cases are classified as atrophic (85-90%) or exudative (10-15%).
Treatment options for exudative AMD are well established and effective, but
therapies designed to treat atrophic AMD are just now beginning to fully be
explored. In order to better study the therapeutic efficacy of anti-complementbased therapy for the treatment of dry AMD, we used a chronic cigarette smoke
model in mice. A large body of literature exists linking this model to elements of
AMD pathology. Endoplasmic reticulum stress markers were found to be elevated
in the RPE of mice after 6 months of cigarette smoke exposure [224]. Chronic
cigarette smoke exposure has been shown to result in the formation of sub-RPE
deposits and a thickening of BrM [152], in addition to ultrastructural damage to
the RPE and BrM and RPE cell apoptosis [66]. Nakayama and colleagues
showed that 12 weeks of exposure to mainstream cigarette smoke can cause
CNV in mice, providing a link to exudative AMD as well [237]. Although much of
the pathology of AMD has already been established, the exact mechanisms
underlying the disease remain to be elucidated.
Mechanisms of AMD
AMD is a complex disease, likely influenced by a number of different
factors. The primary mechanisms involved in the pathogenesis of AMD,
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highlighting contributions from cigarette smoke, are outlined below (Fig. 4.1).
These include oxidative damage, impaired choroidal circulation, and complement
activation. Oxidative damage in AMD is a result of oxidative stress and
antioxidant depletion. The RPE is under a high degree of oxidative stress at
baseline due to the turnover of photoreceptors. Smoking increases this oxidative
load via the introduction of smoke-derived free-radicals [64] and depletion of the
antioxidant system [129]. Zafrilla and colleagues demonstrated that AMD patients
display an altered metabolic state of oxidation-reduction, via decreased levels of
SOD activity, glutathione reductase, and glutathione peroxidase [238]. Oxidative
damage can cause problems with ocular blood flow and endothelial function that
is amenable to antioxidant treatment. Pemp and colleagues found that
antioxidants reduced oxidative-stress induced endothelial dysfunction, possibly
by eliminating ROS [239].
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Figure 4.1 Mechanisms of AMD pathogenesis. The primary mechanisms involved in
the pathogenesis of AMD, particularly as they relate to cigarette smoke are depicted.
Oxidative damage, complement activation, and impaired choroidal circulation all
contribute to RPE degradation and drusen formation, the two hallmark features of
atrophic AMD. The disease can then progress to the exudative form as new vessels
infiltrate the compromised RPE/BrM.

Impaired choroidal circulation may be a result of vasoconstriction and
thrombosis. Nicotine, a primary constituent of cigarette smoke, exerts
vasoconstriction via alpha-adrenergic receptor activation. This mechanism of
vasoconstriction may be associated with an increased risk of developing AMD in
smokers. The expression of nitric oxide synthase was found to be reduced in
AMD eyes compared to controls [240]. Nitric oxide production by vascular
endothelium is essential for the regulation of blood flow, and low levels of NOS
may be associated with vasoconstriction and hemodynamic changes observed in
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AMD. A positive correlation was found between plasma fibrinogen levels and
AMD [241] and exudative AMD [242]. Fibrinogen is a glycoprotein thats helps in
the formation of blood clots. Furthermore, cigarette smoke, a primary risk factor
for AMD, causes changes in clot dynamics and altered fibrin architecture,
contributing to heightened thrombogenicity [40].
The association of inflammation with AMD pathogenesis is well
established. Serum markers of inflammation (high-sensitivity C-reactive protein,
tumor necrosis factor-alpha receptor 2, interluekin-6) were found to be
associated with the incidence of early AMD [243]. Inflammation is likely due to
enhanced activation of complement components in conjunction with a decrease
in the amount of complement inhibitors. Numerous studies have demonstrated
the presence of complement components in drusen and the RPE of AMD
patients [136, 209, 244], suggesting that the complement system is more active
in these individuals. Furthermore, gene variants for these complement proteins
have been linked to AMD risk [245]. Johnson and colleagues suggested that CFH
dysfunction may lead to excessive inflammation and tissue damage in AMD
[246]. Introduction of CR2-FH, a recombinant form of CFH, was shown to reduce
RPE injury and angiogenesis in a mouse model of AMD [81].
Treatments for AMD
Currently, the only therapy available for dry AMD is the daily intake of
antioxidants. Since the retina is highly susceptible to oxidative stress,
administration of antioxidants may prevent damage stemming from ROS.
According to the AREDS, the use of antioxidants (vitamin C, vitamin E, and beta-
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carotene) plus zinc and copper reduced the odds of developing advanced AMD
in a randomized control trial [247]. Smailhodzic and colleagues showed that daily
intake of zinc supplements for 3 months significantly reduced excessive systemic
complement activation in AMD patients [248]. This finding suggests that the
therapeutic efficacy of zinc is linked to regulation of the complement system,
which left unchecked can lead to the accumulation of subretinal deposits. It is
important to note that in these studies the benefit of antioxidant intake is limited
to delaying the progression of AMD. A review conducted by Chong and
colleagues demonstrated that vitamin A, vitamin C, vitamin E, zinc, lutein,
zeaxanthin, alpha- and beta-carotene, beta-cryptoxanthin, and lycopene had little
or no effect in the primary prevention of early AMD [249]. Vitamins B9, B12, and
B6 are studied for their ability to decrease serum levels of homocysteine which, if
elevated, can increase susceptibility to endothelial injury and inflammation. In a
randomized trial conducted by Christen and colleagues, individuals who took
daily supplements of vitamins B9, B12, and B6 had a decreased risk of
developing AMD [250].
New therapeutic strategies for dry AMD are being explored targeting
drusen formation, inflammation, oxidative stress, accumulation of toxic byproducts, choroidal perfusion, RPE cells, and photoreceptors [251]. Several
studies show a correlation between AMD drusen and AD plaques, since both
contain amyloid-beta along with activated complement components [7, 252, 253].
Glatiramer acetate is a novel drug in testing that has been shown to reduce both
AD plaques and drusen formation in mouse models of AMD [254, 255]. Reduced
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drusen formation can alleviate the blockage of nutrient and waste exchange at
the RPE/BrM/CC interface, thereby allowing the RPE to function normally. Other
therapeutics in development for reducing inflammation aim to eliminate excessive
activation of complement, thereby reducing subsequent immune-mediated
damage to the RPE. Lampalizumab, an antibody against CFD, has been shown
to reduce GA lesion progression by 20.4% at 18 months following monthly
intravitreal injection in AMD patients [235]; this reduction was increased to 44% in
a subpopulation that was positive for the complement factor I biomarker.
Neuroprotective drugs such as brimonidine tartrate, an alpha-2 adrenergic
receptor agonist, help to reduce oxidative stress by preventing apoptosis of
viable photoreceptors. Brimonidine tartrate has been shown to stimulate the
production of neurotrophic factors and preserve photoreceptor cells in rats
following retinal ischemic injury [256]. These drugs, which provide
neuroprotection for photoreceptors, are benefical in preserving visual function.
Fenretinide and ALK-001 are two drugs in development to slow down
photoreceptor activity, thereby reducing the accumulation of toxic by-products
from the visual cycle such as N-retinylidene-N-retinylethanolamine (A2-E) and
lipofuscin. Photooxidation of these by-products is postulated to trigger
complement attack, predisposing the RPE to disease and chronic inflammation
[257]. Fenretinide decreases the amount of vitamin A, a necessary component
for A2-E biosynthesis, and also reduces angiogenesis and inflammation [258].
ALK-001 is a modified vitamin A that is unable to dimerize with other vitamin A
molecules to form A2-E and lipofuscin [259]. Other drugs have been tested for
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their efficacy in enhancing choroidal circulation. Sildenafil, a potent
phosphodiesterase 5 inhibitor, induces vasodilation of smooth muscle and has
been shown to enhance choroidal blood flow [260]. Enhanced choroidal blood
flow may improve RPE viability by supporting increased nutrient/waste exchange.
Finally, a new approach has recently emerged which employs the use of
embryonic stem cells isolated from human blastocysts. These cells are
pluripotent in vitro and capable of differentiating into new RPE or photoreceptor
cells based on how they are stimulated. Transplantation of rod precursors has
been shown to improve vision in mice lacking rod function [261, 262]. A recent
study followed dry AMD patients one year following subretinal transplantation of
human embryonic stem cell-derived RPE, and reported a significant increase in
visual acuity with no evidence of adverse proliferation, tumorigenicity, or ectopic
tissue formation [263].
Wet AMD is characterized by abnormal blood vessel growth from the
choroid into the subretinal space, where blood and fluids cause degeneration of
the light-sensitive photoreceptors. Therefore, the main goal in the treatment of
exudative AMD is to inhibit CNV [264]. Initially, treatment options for wet AMD
were limited to laser techniques. Gerhard Meyer-Schwickerath, a German
ophthalmologist, was the first to experiment with an optical method to coagulate
the retina using a focused beam of light [265]. Now called laser
photocoagulation, this outpatient procedure utilizes a high-energy laser beam to
focus on areas of CNV, which cauterizes invading blood vessels. However, scar
formation can occur at the site of the burn, and this may cause a permanent blind
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spot in the patient’s visual field. Additionally, most patients require retreatment
after 2-3 years due to the invasion of new blood vessels. Only about 15% of
patients with exudative AMD can be effectively treated with laser
photocoagulation [266]. One reason for this is that laser photocoagulation is most
effective when CNV is clustered close together. Blood vessels scattered over a
wide area are much more difficult to treat using this method and typically result in
a poor clinical outcome.
Photodynamic therapy (PDT) is similar to thermal laser treatment, but
utilizes a low-power, “cool” laser in conjunction with a light-activated drug known
as a photosensitizer. Photosensitizers, in the presence of oxygen, produce highly
reactive, short-lived singlet oxygen and other ROS when stimulated by light,
resulting in local damage to surrounding cells. The photosensitizer, verteporfin
(Visudyne), is commonly used in the treatment of wet AMD, because it causes
endothelial damage and blood vessel blockage following light activation [267].
The PDT procedure begins with an injection of a photosensitizer into the patient’s
arm, where it enters systemic circulation and spreads to abnormal target vessels
beneath the retina. Next, a low-power laser is focussed directly on areas of CNV,
which activates the photosensitizer and, in turn, destroys the problem
vasculature. Multiple treatments are often required with this therapy due to the
fact that vessels may reopen. Although PDT has been shown to reduce visual
acuity loss associated with the natural progression of exudative AMD [268], many
patients still develop moderate or severe vision loss after treatment [269, 270].
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Anti-angiogenic therapy is the most common treatment used for patients
with wet AMD. In 1956, George Wise postulated that “pure retinal
neovascularization is directly related to a tissue state of relative retinal anoxia.
Under such circumstances, an unknown factor x develops in this tissue and
stimulates new vessel formation, primarily from the capillaries and veins” [271].
This “factor x,” known today as VEGF, is a potent angiogenic factor involved in
bone formation [272], wound healing [273], and development [274]. Blocking
VEGF reduces the growth of abnormal blood vessels, resulting in decreased
leakage, attenuated photoreceptor cell loss, and ultimately, a slower rate of vision
loss. The most common anti-VEGF drugs used today are bevacizumab (Avastin),
ranibizumab (Lucentis), and aflibercept (Eylea). Although recent studies have
shown that bevacizumab and ranibizumab increase visual acuity in patients with
wet AMD [275, 276]; however, bevacizumab has not been approved for
intraocular use by the US FDA. The newest of the three, aflibercept, has the
same efficacy as monthly intravitreal injections of ranibizumab, but only requires
injections every 8 weeks [277]. However, off-label usage of bevacizumab is often
preferred due to the cheaper costs associated with the drug. These drugs are
administered via intravitreal injection into the patient’s eye. Typically, injections
must be given on a monthly basis to maintain therapeutic efficacy. Although this
treatment often provides great benefit for patients, the frequency is often
associated with a significant financial and physical burden.
In addition to the classic anti-VEGF therapies, other mediators of VEGF
expression are being targeted in the treatment of exudative AMD. Transforming
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growth factor-beta (TGF-β) is one such mediator that participates in cell
proliferation and differentiation during angiogenesis. Studies show that TGF-β
significantly enhances VEGF secretion and vascular permeability along with
other cytokines such as necrosis factor alpha [278, 279]. Thus, TGF-β inhibition
may be a useful adjunctive therapeutic strategy for use with anti-VEGF therapy.
Semaphorin 3A is a potent chemorepellent guidance molecule involved in axonal
growth cone guidance and vessel network formation [280, 281]. Bai and
colleagues showed that semaphorin 3A inhibited laser-induced CNV formation in
mice and inhibited the uptake of VEGF and TGF-β [282]. Alternative targets for
the treatment of wet AMD are macrophages which play a critical role in the
development of CNV. Tumor necrosis factor-inducible gene 6 protein (TSG-6) is
an endogenous protein involved in extracellular matrix stability, cell migration,
and regulating macrophage activation. Kim and colleagues demonstrated that
TSG-6 suppressed the expression of VEGF and pro-inflammatory cytokines,
inhibited recruitment of CCR2(+) monocytes, and reduced the size of CNV
lesions in mice following laser-induced CNV formation.
Conclusions
We can draw several conclusions based on the results of this study. First,
we have demonstrated that the cigarette smoke model is a useful tool for
studying AMD pathology. A number of parallels exist between the clinical
presentation of AMD patients and observations noted from mice exposed to
chronic cigarette smoke for 6 months. Poor contrast sensitivity was the first
parallel observed in mice following CE, measured using the OKR test. A recent
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study reported that AMD patients had significantly lower scores in the Spaeth/
Richman Contrast Sensitivity test versus controls [283]. The second parallel
observed in smoke-exposed animals was the presence of extracellular deposits
in BrM, visualized using electron microscopy. These deposits are reminiscent of
drusen, the hallmark sign of dry AMD. In fact, the only notable difference
between the two is the location in which they are found. Drusen are found
between the basement membrane of the RPE and the ICL of BrM, while the
deposits we observed were present in the area between the OCL of BrM and the
basement membrane of the CC. The presence of these OCL deposits in mice
exposed to CE was accompanied by an overall thickening of BrM. This finding
corresponds to human studies that report a thickening of BrM in patients with dry
AMD [284], marking a third parallel between the cigarette smoke model and
AMD. The fourth and final parallel observed was a thinning of the ONL,
determined via OCT and histological analysis. The primary clinical characteristic
of advanced stage, dry AMD is GA. These areas of hypopigmentation,
representing areas of RPE degeneration, lead to islands of lost photoreceptors.
Photoreceptor atrophy has been quantified in patients with AMD via a thinning of
the ONL [10]. The cause of ONL thinning observed in smoke-exposed mice likely
differs from that observed in AMD patients with GA. If ONL thinning was a result
of lost photoreceptors, we would expect to see differences in spatial frequency
and photoreceptor cell count, which we did not. Instead, we noticed a decrease
in contrast sensitivity along with a reduction in expression of cone opsins and
RPE65, suggesting a decrease in photoreceptor sensitivity. This decrease in
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sensitivity may be due to Müller cell atrophy, which is the likely cause of the ONL
thinning observed in our experiments. Our findings validate the cigarette smoke
model and its application in studying AMD, particularly the atrophic form of the
disease.
Second, we have demonstrated that the AP of complement plays an
integral role in the development of cigarette smoke-induced ocular pathology.
Using a CFB knockout mouse, we were able to selectively inhibit the AP of
complement, while maintaining the classical and lectin pathways. We found that
these animals were unaffected by cigarette smoke in almost every metric. By
comparison, WT mice exposed to long-term cigarette smoke inhalation exhibited
functional (ERG) and behavioral (OKR) deficits in retinal function, alterations in
gene regulation pathways (photoreceptor signal transduction, RPE cell
metabolism, complement activation, angiogenesis), morphological changes in
RPE-BrM (thickening of BrM, deposit formation in the OCL of BrM, dislocated
mitochondria), and retinal thinning (ONL, INL). The robust differences observed
between WT and CFB knockout animals following long-term smoke exposure
suggest that the AP is necessary for induction of smoke-induced ocular damage.
Several CFB polymorphisms have been characterized as protective against
AMD. The rs641153 allele of CFB is protective against large drusen and drusen
covered area [285], which are positively correlated with risk for developing AMD.
A meta-analysis conducted by Thakkinstian and colleagues reported that the
rs4151667 and rs641153 alleles of CFB carried estimated risks of 0.54 and 0.41
(odds ratios), respectively, conferring a reduced risk of developing AMD [286].
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Another study showed that deletions of CFH-related genes CFHR3 and CFHR1
is protective against AMD. CFHR3 and CFHR1 compete with CFH for binding to
C3. Therefore, a deficiency of CFHR3 and CFHR1 is thought to enhance local
regulation of the AP by CFH [287]. Taken together, these findings suggest that
the AP of complement plays a pivotal role in the development of cigarette smokeinduced ocular pathology and AMD.
Finally, we have shown that smoke-induced ocular pathology is amenable
to anti-complement-based therapy. Mice were exposed to cigarette smoke for 6
months, then treated under room air conditions for 3 months with a modified
version of CFH, an AP inhibitor, to determine if smoke-induced ocular pathology
is reversible. Specifically, we wanted to know whether smoke pathology can be
reduced after cessation. We found that smoke-exposed mice treated with CR2FH exhibited normal visual acuity, retinal morphology, and retinal thickness
compared to vehicle controls. These findings provide additional support for our
hypothesis that the AP of complement is necessary for the development of longterm smoke-induced ocular pathology. Additionally, these findings suggest that
CR2-FH can effectively reverse retinal deficits associated with cigarette smoke
pathology, and provide a platform to test the efficacy of CR2-FH for the treatment
of AMD. The Y402H risk variant of CFH, which is associated with an increased
risk of developing AMD, was correlated with AP complement activation [288].
However, the beneficial effects of CFH extends beyond its inhibitory action on the
AP. Weismann and colleagues showed that CFH binds to MDA, a common lipid
peroxidation product found in AMD, and blocks the uptake of MDA-modified
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proteins by macrophages in mice [125]. Taken together, these findings suggest
that anti-complement-based therapies, such as CR2-FH, may provide a powerful
new therapeutic approach for treating AMD. The present study provides a
foundation for the exploration of novel anti-complement-based therapies for use
in the treatment of AMD, but further research needs to be conducted to fully
elucidate the mechanisms underlying the disease. Future studies using aged
mice may provide a more accurate model of dry AMD. Also, the influence of
gender on cigarette smoke pathology remains to be elucidated (i.e. the
interaction of CE and menopausal changes in estrogen levels). Finally, the role of
the classical and lectin pathways of complement in smoke-induced ocular
pathology still requires investigation.
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Appendix
Detection of CFB and RD8 Mutations by PCR
PCR-ready DNA was prepared from mouse tail biopsy samples using
HotSHOT alkaline lysis and neutralizing reagents [289]. PCR amplification for
each reaction was carried out using 15 µl of GoTaq green master mix (Promega,
M7122), 10 µl of nuclease-free water, and 1 µl of each diluted primer per 5 µl of
DNA template. PCR primers for complement factor B (CFB) deficiency detection
were as follows: 5’-CCGAAGCATTCCTATCCTCC-3’, 5’CAGATGGGCTGACCGCTTCC-3’, and 5’CTAGTCTTGTCTGCTTTCTCC-3’ [290]. Reactions for CFB were initially
denatured at 95˚C for 5 minutes followed by 38 cycles at 95˚C for 60 seconds,
54˚C for 60 seconds, 72˚C for 60 seconds, and a final extension at 72˚C for 10
minutes. Amplified DNA samples for CFB mutation detection were run with an
aliquot of GeneRuler 100 bp Plus DNA ladder (Fermentas, SM0323). Amplicon
sizes for the CFB wild type and mutant allele is equal to 748 and 610 bp,
respectively. Primer sequences for the detection of an RD8 mutation included
mCrb 1, mF1: 5’-GTGAAGACAGCTACAGTTCTGATC-3’; mCrb 1, mF2: 5’GCCCCTGTTTGCATGGAGGAAACTTGGAAGACAGCTACAGTTCTTCTG-3’;
and mCrb 1, mR: 5’-GCCCCATTTGCACACTGATGAC-3’ [291]. In order to get
the best PCR amplification results of RD8 sequences, the mF1 and mR primer
amounts were doubled to compensate for the larger mF2 primer. PCR reactions
for RD8 were denatured at 94˚C for 5 minutes followed by 35 cycles at 94˚C for
30 seconds, 65˚C for 30 seconds, 72˚C for 30 seconds, and a final extension at

117

72˚C for 10 minutes. Amplified DNA samples for RD8 mutation detection were
run against the 50 bp HyperLadderV (Bioline, BIO-33057). Amplicon sizes for the
RD8 wild type and mutant allele is equal to 220 and 244 bp, respectively. Since
the RD8 wild type and mutant amplification products have a similar molecular
weight, primer set reactions were carried out separately for each DNA template.
Amplified DNA samples and corresponding ladders were separated using a 1.5%
agarose gel containing ethidium bromide and visualized under UV light.
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